sbbp_Current Folio

0001558370-20-005292.txt : 20200506 0001558370-20-005292.hdr.sgml : 20200506 20200506080117 ACCESSION NUMBER: 0001558370-20-005292 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 62 CONFORMED PERIOD OF REPORT: 20200331 FILED AS OF DATE: 20200506 DATE AS OF CHANGE: 20200506 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Strongbridge Biopharma plc CENTRAL INDEX KEY: 0001634432 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 981130690 STATE OF INCORPORATION: L2 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-37569 FILM NUMBER: 20851193 BUSINESS ADDRESS: STREET 1: 900 NORTHBROOK DRIVE, SUITE 200 CITY: TREVOSE STATE: PA ZIP: 19053 BUSINESS PHONE: (610) 254-9200 MAIL ADDRESS: STREET 1: 900 NORTHBROOK DRIVE, SUITE 200 CITY: TREVOSE STATE: PA ZIP: 19053 FORMER COMPANY: FORMER CONFORMED NAME: Cortendo AB DATE OF NAME CHANGE: 20150219 10-Q 1 sbbp-20200331x10q.htm 10-Q sbbp_Current Folio_10Q

Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Quarterly Period Ended March 31, 2020

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Transition Period from _____________ to _____________

Commission file number 001-37569

Strongbridge Biopharma plc

(Exact name of Registrant as specified in its charter)

Ireland

98-1275166

(State or other jurisdiction of

incorporation or organization)

(I.R.S. Employer

Identification Number)

900 Northbrook Drive

Suite 200

Trevose, PA 19053

(Address of principal executive offices)

Registrant’s Telephone Number, Including Area Code: +1 610‑254‑9200

Securities Registered Pursuant to Section 12(b) of the Exchange Act:


Title of each class:	Trading Symbol	Name of each exchange on which registered:
Ordinary shares, par value $0.01 per share	SBBP	The Nasdaq Global Select Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and emerging growth company in Rule 12b-2 of the Exchange Act.


Large Accelerated Filer	☐	Accelerated Filer	☒

Non-Accelerated Filer	☐	Smaller Reporting Company	☒

		Emerging Growth Company	☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of May 1, 2020, there were 54,247,501 ordinary shares of the registrant issued and outstanding.

Table of Contents

TABLE OF CONTENTS


		Page
PART I.	Financial Information	1

Item 1.	Financial Statements	1
	Consolidated Balance Sheets as of March 31, 2020 and December 31, 2019	1
	Consolidated Statements of Operations and Comprehensive Loss for the Three Months Ended March 31, 2020 and 2019	2
	Consolidated Statements of Stockholders’ Equity	3
	Consolidated Statements of Cash Flow for the Three Months Ended March 31, 2020 and 2019	4
	Notes to the Unaudited Consolidated Financial Statements	5

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	14
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	21
Item 4.	Controls and Procedures	21

PART II.	Other Information	22

Item 1.	Legal Proceedings	22
Item 1A.	Risk Factors	22
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	23
Item 3.	Defaults Upon Senior Securities	23
Item 4.	Mine Safety Disclosures	23
Item 5.	Other Information	23
Item 6.	Exhibits	24

SIGNATURES		25

Solely for convenience, the trademarks and trade names in this Quarterly Report on Form 10-Q (this “Quarterly Report”) are referred to without the ® and ™ symbols, but absence of such references should not be construed as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto. The trademarks, trade names and service marks appearing in this Quarterly Report are the property of their respective owners.

Table of Contents

PART I – FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

STRONGBRIDGE BIOPHARMA plc

Consolidated Balance Sheets

(In thousands, except share and per share data)

(unaudited)


	March 31,		December 31,
	2020		2019
ASSETS
Current assets:
Cash and cash equivalents	$	56,554	$	57,032
Marketable securities		6,293		21,072
Accounts receivable		2,690		2,289
Inventory		1,343		1,993
Prepaid expenses and other current assets		1,078		1,157
Total current assets		67,958		83,543
Property and equipment, net		270		291
Right of use asset, net		744		789
Intangible asset, net		23,855		25,110
Goodwill		7,256		7,256
Other assets		977		649
Total assets	$	101,060	$	117,638
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$	5,285	$	3,331
Accrued and other current liabilities		18,513		20,962
Total current liabilities		23,798		24,293
Warrant liability		3,547		4,127
Supply agreement liability, noncurrent		11,556		15,947
Other long-term liabilities		980		1,080
Total liabilities		39,881		45,447
Commitments and contingencies (Note 8)
Stockholders’ equity:
Deferred shares, $1.098 par value, 40,000 shares authorized, issued and outstanding at March 31, 2020 and December 31, 2019		44		44
Ordinary shares, $0.01 par value, 600,000,000 shares authorized at March 31, 2020 and December 31, 2019; 54,247,501 and 54,205,852 shares issued and outstanding at March 31, 2020 and December 31, 2019		542		542
Additional paid-in capital		333,768		332,085
Accumulated deficit		(273,181)		(260,483)
Accumulated other comprehensive income		6		3
Total stockholders’ equity		61,179		72,191
Total liabilities and stockholders’ equity	$	101,060	$	117,638

The accompanying notes are an integral part of these unaudited consolidated financial statements.

Table of Contents

STRONGBRIDGE BIOPHARMA plc

Consolidated Statements of Operations and Comprehensive Loss

(In thousands, except share and per share data)

(unaudited)


	Three Months Ended
	March 31
	2020		2019
Revenues:
Net product sales	$	6,663	$	4,333
Royalty revenue		11		10
Total revenues		6,674		4,343

Cost and expenses:
Cost of sales (excluding amortization of intangible asset)	$	969	$	813
Selling, general and administrative		10,403		12,100
Research and development		7,552		6,583
Amortization of intangible asset		1,256		1,256
Total cost and expenses		20,180		20,752
Operating loss		(13,506)		(16,409)
Other income (expenses), net:
Unrealized gain (loss) on fair value of warrants		580		(1,820)
Income from field services agreement		—		2,016
Expense from field services agreement		—		(2,229)
Other income, net		228		685
Total other income (expenses), net		808		(1,348)
Loss before income taxes		(12,698)		(17,757)
Income tax expense		—		(677)
Net loss	$	(12,698)	$	(18,434)
Other comprehensive income
Unrealized gain on marketable securities		3		—
Comprehensive loss	$	(12,695)	$	(18,434)

Net loss attributable to ordinary shareholders:
Basic	$	(12,698)	$	(18,434)
Diluted	$	(13,278)	$	(18,434)
Net loss per share attributable to ordinary shareholders:
Basic	$	(0.23)	$	(0.34)
Diluted	$	(0.24)	$	(0.34)
Weighted-average shares used in computing net loss per share attributable to ordinary shareholders:
Basic		54,231,024		54,155,034
Diluted		54,444,681		54,155,034

The accompanying notes are an integral part of these unaudited consolidated financial statements.

Table of Contents

STRONGBRIDGE BIOPHARMA plc

Consolidated Statement of Stockholders’ Equity

(In thousands, except share amounts)

(unaudited)


	Strongbridge Biopharma plc Shareholders
							Additional				Accumulated Other		Total
	Ordinary Shares			Deferred Shares			Paid-In		Accumulated		Comprehensive		Shareholders’
	Shares	Amount		Shares	Amount		Capital		Deficit		Income		Equity
Balance—December 31, 2018	54,122,074	$	541	40,000	$	44	$	323,402	$	(211,032)		—	$	112,955
Net loss	—		—	—		—		—		(18,434)		—		(18,434)
Stock-based compensation	—		—	—		—		2,323		—		—		2,323
Exercise of stock options	39,728		1	—		—		165		—		—		166
Ordinary shares issued, net of shares withheld for employee taxes	6,146		*	—		—		(27)		—		—		(27)
Balance—March 31, 2019	54,167,948	$	542	40,000	$	44	$	325,863	$	(229,466)		—	$	96,983

Balance—December 31, 2019	54,205,852	$	542	—	$	44	$	332,085	$	(260,483)		3	$	72,191
Net loss	—		—	—		—		—		(12,698)		—		(12,698)
Stock-based compensation	—		—	—		—		1,751		—		—		1,751
Ordinary shares issued, net of shares withheld for employee taxes	41,649		*	—		—		(68)		—		—		(68)
Unrealized gain on marketable securities			—	—		—		—		—		3		3
Balance—March 31, 2020	54,247,501	$	542	—	$	44	$	333,768	$	(273,181)		6	$	61,179

* Represents an amount less than $1.

The accompanying notes are an integral part of these unaudited consolidated financial statements.

Table of Contents

STRONGBRIDGE BIOPHARMA plc

Consolidated Statements of Cash Flow

(In thousands)

(unaudited)


	Three Months Ended
	March 31,
	2020		2019
Cash flows from operating activities:
Net loss	$	(12,698)	$	(18,434)
Adjustments to reconcile net loss to net cash used in operating activities:
Change in fair value of warrant liability		(580)		1,820
Stock-based compensation		1,751		2,323
Amortization of intangible asset		1,256		1,256
Accretion of discounts on marketable securities		(48)		—
Depreciation		21		18
Changes in operating assets and liabilities:
Accounts receivable		(401)		(2,290)
Inventory		101		(649)
Prepaid expenses and other current assets		79		1,510
Other assets		266		(1,210)
Accounts payable		1,954		539
Accrued and other liabilities		(6,941)		(3,191)
Net cash used in operating activities		(15,240)		(18,308)
Cash flows from investing activities:
Purchases of property and equipment		—		(15)
Maturities of marketable securities		14,830		—
Net cash provided by (used in) investing activities		14,830		(15)
Cash flows from financing activities:
Proceeds from exercise of stock options		—		166
Payments related to tax withholding for net-share settled equity awards		(68)		(27)
Net cash (used in) provided by financing activities		(68)		139
Net decrease in cash and cash equivalents		(478)		(18,184)
Cash and cash equivalents—beginning of period		57,032		122,490
Cash and cash equivalents—end of period	$	56,554	$	104,306
Supplemental non-cash financing activities:
Changes in unrealized gain on marketable securities	$	3	$	—

The accompanying notes are an integral part of these unaudited consolidated financial statements.

Table of Contents

STRONGBRIDGE BIOPHARMA plc

Notes to Unaudited Consolidated Financial Statements

1. Organization

We are a global, commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs.

Our first commercial product is Keveyis (dichlorphenamide), the first and only treatment approved by the U.S. Food and Drug Administration (the “FDA”) for hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (“PPP”), a group of rare hereditary disorders that cause episodes of muscle weakness or paralysis.

We have two clinical-stage product candidates for rare endocrine diseases, Recorlev and veldoreotide. Recorlev (levoketoconazole) is a cortisol synthesis inhibitor currently being studied for the treatment of endogenous Cushing's syndrome. Veldoreotide is a next-generation somatostatin analog being investigated for potential applications in conditions amenable to somatostatin receptor activation, such as acromegaly. Both levoketoconazole and veldoreotide have received orphan designation from the FDA and the European Medicines Agency (“EMA”).

In January 2018, Strongbridge Ireland Limited, one of our wholly-owned subsidiaries, acquired the U.S. and Canadian rights to Macrilen (macimorelin), the first and only oral drug approved by the FDA for the diagnosis of patients with adult growth hormone deficiency. We launched Macrilen in the United States in July 2018. In December 2018, we sold Strongbridge Ireland Limited to Novo Nordisk Healthcare AG (“Novo”) for $145 million plus the right to receive tiered royalties on net sales of Macrilen through 2027. In addition, Strongbridge U.S. Inc., another of our wholly-owned subsidiaries, entered into an agreement with Novo Nordisk Inc. (“NNI”), a subsidiary of Novo, pursuant to which NNI funded the costs of 23 of our field-based employees to provide full-time ongoing services to NNI, including the promotion of Macrilen in the United States, for a period of three years. Novo also purchased 5.2 million of our ordinary shares at a purchase price of $7.00 per share. In December 2019, we reached an agreement with Novo to terminate the services agreement. We received a $6 million payment in connection with such termination and we no longer provide services to Novo.

Liquidity

We believe that our cash, cash equivalents and marketable securities of $62.8 million at March 31, 2020 will be sufficient to allow us to fund planned operations for at least 12 months beyond the issuance date of these unaudited consolidated financial statements.

We may never achieve profitability, and unless and until we do, we will continue to need to raise additional capital. We plan to continue to fund our operations and capital funding needs through equity or debt financing along with revenues from Keveyis. There can be no assurances, however, that additional funding will be available on terms acceptable to us.

2. Summary of significant accounting policies and basis of presentation

Basis of presentation

These unaudited consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States (“U.S. GAAP”). The unaudited consolidated financial statements reflect all adjustments, which include only normal recurring adjustments that are, in the opinion of management, necessary to present a fair statement of the operating results and financial position for the periods presented.

Table of Contents

financial statements. Actual results could differ from those estimates. Results for the three months ended March 31, 2020 are not necessarily indicative of the results that may be expected for the year ending December 31, 2020.

These unaudited consolidated financial statements should be read in conjunction with the accounting policies and notes to the audited consolidated financial statements included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2019 filed with the U.S. Securities and Exchange Commission on February 28, 2020 (the “2019 Annual Report”). Our significant accounting policies are described in Note 2 of the notes to the audited consolidated financial statements included in our 2019 Annual Report. Since the date of those financial statements, there have been no changes to our significant accounting policies.

Leases

We account for leases in accordance with Accounting Standards Codification Topic 842, Leases, (“ASC 842”). We determine if an arrangement is a lease at contract inception. A lease exists when a contract conveys to us the right to control the use of identified property, plant, or equipment for a period of time in exchange for consideration. The definition of a lease embodies two conditions: (1) there is an identified asset in the contract that is land or a depreciable asset (i.e., property, plant, and equipment), and (2) we have the right to control the use of the identified asset.

Operating leases where we are the lessee are included in Right of use (“ROU”) assets and Other current liabilities and Other long-term liabilities on our Consolidated Balance Sheets. The lease liabilities are initially and subsequently measured at the present value of the unpaid lease payments at the lease commencement date.

Key estimates and judgments include how we determined (1) the discount rate we use to discount the unpaid lease payments to present value, (2) lease term and (3) lease payments.

ASC 842 requires a lessee to discount its unpaid lease payments using the interest rate implicit in the lease or, if that rate cannot be readily determined, its incremental borrowing rate. Because our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. Our incremental borrowing rate for a lease is the rate of interest we would have to pay on a collateralized basis to borrow an amount equal to the lease payments under similar terms.

The lease term for all of our leases includes the noncancellable period of the lease. Lease payments included in the measurement of the lease asset or liability are comprised of our fixed payments.

The ROU asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for lease payments made at or before the lease commencement date less any lease incentives received.

For operating leases, the ROU asset is subsequently measured throughout the lease term at the carrying amount of the lease liability, plus (minus) any prepaid (accrued) lease payments, less the unamortized balance of lease incentives received. Lease expense for lease payments is recognized on a straight-line basis over the lease term.

We monitor for events or changes in circumstances that require a reassessment of a lease. If a reassessment results in the remeasurement of a lease liability, a corresponding adjustment is made to the carrying amount of the corresponding ROU asset unless doing so would reduce the carrying amount of the ROU asset to an amount less than zero. In that case, the amount of the adjustment that would result in a negative ROU asset balance is recorded in profit or loss.

We have elected not to recognize ROU assets and lease liabilities for all short-term leases that have a lease term of 12 months or less. We recognize the lease payments associated with our short-term leases as an expense on a straight-line basis over the lease term. Variable lease payments associated with these leases are recognized and presented in the same manner as for all our other leases.

Table of Contents

We adopted ASC 842 using a modified retrospective transition approach as of the effective date, as permitted by the amendments in ASU 2018-11. As a result, we were not required to adjust our comparative period financial information for effects of the standard or make the new required lease disclosures for periods before the date of adoption (i.e., January 1, 2019). We have elected to adopt the package of transition practical expedients and, therefore, have not reassessed (1) whether existing or expired contracts contain a lease, (2) lease classification for existing or expired leases or (3) the accounting for initial direct costs that were previously capitalized. We did not elect the practical expedient to use hindsight for leases existing at the adoption date. Further, we do not expect the amendments in ASU 2018-01: Land Easement Practical Expedient to have an effect on us because we do not enter into land easement arrangements.

Cash, cash equivalents and marketable securities

We consider all short‑term highly liquid investments with an original maturity at the date of purchase of three months or less to be cash equivalents. Cash and cash equivalents consist of account balances at banks and money market accounts, respectively.

We invest our excess cash balances in marketable securities of highly rated financial institutions. We seek to diversify our investments and limit the amount of investment concentrations for individual institutions, maturities and investment types. We classify marketable debt securities as available-for-sale and, accordingly, record such securities at fair value. We classify these securities as current assets as these investments are intended to be available to us for use in funding current operations. There were no marketable securities with a maturity of greater than one year as of March 31, 2020.

Unrealized gains and losses on marketable debt securities are recorded as a separate component of accumulated other comprehensive income (loss) included in stockholders’ equity.

Segment information

Operating segments are identified as components of an enterprise for which separate discrete financial information is available for evaluation by the chief operating decision maker, or decision making group, in making decisions on how to allocate resources and assess performance. We view our operations and manage our business in one operating segment.

Net loss per share

Basic net loss per share is calculated by dividing the net loss attributable to shareholders by the weighted average number of ordinary shares outstanding during the period. Diluted net loss per share is calculated by dividing the net loss attributable to shareholders by the weighted‑average number of ordinary shares outstanding for the period, including any dilutive effect from outstanding stock options or other equity-based awards. Shares used in the diluted net loss per share calculations exclude anti‑dilutive ordinary share equivalents, which currently consist of outstanding stock options, unvested restricted stock units (“RSUs”) and equity-classified warrants.

The following potentially dilutive securities have been excluded from the computations of diluted weighted average shares outstanding as of March 31, 2020 and 2019, as they would be anti-dilutive:


	March 31,
	2020		2019
Warrants		1,803,253		6,833,253
Stock options issued and outstanding		10,334,368		10,205,851
Unvested RSUs		925,800		758,850

Table of Contents

Recent accounting pronouncements – not yet adopted

In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments. ASU 2016-13 requires an entity to measure and recognize expected credit losses for certain financial instruments, including trade receivables, as an allowance that reflects the entity's current estimate of credit losses expected to be incurred. For available-for-sale debt securities with unrealized losses, the standard requires allowances to be recorded through net income instead of directly reducing the amortized cost of the investment under the current other-than-temporary impairment model. The standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019 for SEC filers, excluding smaller reporting companies, who have until fiscal years beginning after December 15, 2022. We do not expect the adoption of this standard to have a significant impact on our financial statements or internal controls.

3. Revenue recognition

Product sales, net

We sell Keveyis to one specialty pharmacy provider (the “Customer”), who is the exclusive distributor of Keveyis in the United States. The Customer subsequently resells Keveyis to patients, most of whom are covered by payors that may provide for government-mandated or privately negotiated rebates with respect to the purchase of Keveyis.

Revenues from sales of Keveyis are recognized when we satisfy a performance obligation by transferring control of the product to the Customer. Transfer of control occurs upon receipt of the product by the Customer. We expense incremental costs related to the set-up of contracts with the Customer when incurred, as these costs do not meet the criteria for capitalization.

Reserves for variable consideration

Revenues from sales of Keveyis are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established and that result from rebates, co-pay assistance and other allowances that are offered between us and the patients’ payors. There is no variable consideration reserve for returns as we do not accept returns of Keveyis. These reserves are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to the Customer) or a current liability (if the amount is payable to a party other than the Customer). Where appropriate, these estimates may take into consideration a range of possible outcomes that are probability-weighted for relevant factors such as our historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. Overall, these reserves reflect our best estimates of the amount of consideration to which we are entitled based on the terms of the contract. The amount of variable consideration that is included in the transaction price may be constrained, and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. Actual amounts of consideration ultimately received may differ from our estimates. We reassess our estimates on an ongoing basis. If actual results in the future vary from our estimates, we will adjust our estimates. Any such adjustments would affect net product revenue and earnings in the period such variances become known.

Trade Discount: We provide the Customer with a discount that is explicitly stated in our contract and is recorded as a reduction of revenue in the period the related product revenue is recognized. In addition, we receive sales order management, data and distribution services from the Customer. To the extent the services received are distinct from our sale of Keveyis to the Customer, these payments are classified in selling, general and administrative expenses in our consolidated statement of operations and comprehensive loss.

Funded Co-pay Assistance Program: We contract with a third-party to manage the co-pay assistance program intended to provide financial assistance to qualified insured patients. The calculation of the accrual for co-pay assistance

Table of Contents

is based on an estimate of claims and the cost per claim that we expect to receive associated with Keveyis that has been recognized as revenue, but remains in the distribution channel inventories at the end of each reporting period. These payments are consideration payable to the Customer and the related reserve is recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability which is included in accrued expenses on the consolidated balance sheet.

Government Rebates: We are subject to discount obligations under state Medicaid programs and Medicare. We estimate our Medicaid and Medicare rebates for the estimated patient mix. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability, which is included in accrued expenses on the consolidated balance sheet. For Medicaid, accruals are based on estimates of future Medicaid beneficiary utilization applied to the Medicaid unit rebate formula established by the Center for Medicaid and Medicare Services. Effective January 1, 2019, manufacturers of pharmaceutical products are responsible for 70% of the patient’s cost of branded prescription drugs related to the Medicare Part D Coverage Gap. In order to estimate the cost to us of this Medicare coverage gap responsibility, we estimate the number of patients in the prescription drug coverage gap for whom we will owe an additional liability under the Medicare Part D program. Our liability for these rebates consists of estimates of claims for the current quarter and estimated future claims that will be made for Keveyis that have been recognized as revenue, but remains in the distribution channel inventories at the end of each reporting period.

Temporary Supply and Patient Assistance Programs: We provide free Keveyis to uninsured patients who satisfy pre-established criteria for either the Temporary Supply Program or the Patient Assistance Program. Patients who meet the Temporary Supply Program eligibility criteria may receive a temporary supply of free Keveyis for no more than sixty days while there is a determination of the patient’s third-party insurance, prescription drug benefit or other third-party coverage for Keveyis. The Patient Assistance Program provides free Keveyis for up to twelve months to uninsured patients who satisfy pre-established criteria for financial need. We do not recognize any revenue related to these free products and the associated costs are classified in selling, general and administrative expenses in our consolidated statements of operations and comprehensive loss.

4. Fair value measurement

We follow FASB accounting guidance on fair value measurements for financial assets and liabilities measured on a recurring basis. Because of their short-term nature, the amounts reported in the balance sheet for cash and accounts payable approximate fair value.

The guidance requires fair value measurements to maximize the use of “observable inputs.” The three-level hierarchy of inputs to measure fair value are as follows:

Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities. Because of their short-term nature, the amounts reported in the balance sheet for cash and accounts payable approximate fair value.

Level 2: Significant observable inputs other than Level 1 prices such as quoted prices in markets that are not active, or inputs that are observable, either directly or indirectly, for substantially the full term of the asset or liability

Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity). The fair values of the outstanding warrants were measured using the Black-Scholes option-pricing model. Inputs used to determine estimated fair value of the warrant liabilities include the estimated fair value of the underlying stock at the valuation date, the estimated term of the warrants, risk-free interest rates, and the expected volatility of the underlying stock. The significant unobservable inputs used in the fair value measurement of the warrant liabilities were the volatility rate and the estimated term of the warrants. Generally, increases (decreases) in the fair value of the underlying stock and estimated term would result in a directionally similar impact to the fair value measurement.

Table of Contents

We did not have any transfers between the different levels.

The following table presents our assets and liabilities that are measured at fair value on a recurring basis for the periods presented (in thousands):


	As of March 31, 2020
	Level I		Level II		Level III		Total
Cash equivalents		56,078		—		—		56,078
Marketable securities		—		6,293		—		6,293
Total assets	$	56,078	$	6,293	$	—	$	62,371
Warrant liability		—		—		3,547		3,547
Total liabilities	$	—	$	—	$	3,547	$	3,547


	As of December 31, 2019
	Level I		Level II		Level III		Total
Cash equivalents		56,544		—		—		56,544
Marketable securities		—		21,072		—		21,072
Total assets	$	56,544	$	21,072	$	—	$	77,616
Warrant liability		—		—		4,127		4,127
Total liabilities	$	—	$	—	$	4,127	$	4,127

The following table presents a reconciliation of our level 3 warrant liability (in thousands):


		As of March 31, 2020
Balance as of December 31, 2019	$	4,127
Unrealized gain on fair value of warrants for three months ended March 31, 2020		(580)
Balance as of March 31, 2020	$	3,547

5. Marketable securities

Marketable securities consist of the following:


	As of March 31, 2020
	Amortized Cost		Net Unrealized Gain		Fair Value
Commercial paper	$	3,293	$	—	$	3,293
U.S. treasury securities		2,994		6		3,000
Total marketable securities	$	6,287	$	6	$	6,293

6. Intangible asset and goodwill

The following represents the balance of our intangible asset and goodwill as follows (in thousands):


	As of March 31, 2020
	Beginning of Period		Amortization		End of Period
Keveyis	$	25,110	$	(1,256)	$	23,855
Goodwill		7,256		—		7,256
Total	$	32,366	$	(1,256)	$	31,111

Our finite-lived intangible asset consists of acquired developed product rights obtained from our acquisition of Keveyis (dichlorphenamide) from a subsidiary of Taro Pharmaceutical Industries Ltd. (“Taro”).

Table of Contents

Pursuant to the terms of the Asset Purchase Agreement and Supply Agreement that we entered into with Taro in December 2016, we paid Taro an upfront payment in two installments of $1 million in December 2016 and $7.5 million in March 2017. We concluded that the supply price payable by us exceeds fair value and, therefore, used a discounted cash flow method with a probability assumption to value the payments in excess of fair value at $29.3 million, for which we have recorded an intangible asset and corresponding liability. This liability is being reduced as we purchase inventory over the term of the Supply Agreement that we entered into with Taro. In addition, we incurred transaction costs of $2.4 million. The transaction resulted in the recording of an intangible asset of $40.2 million. This asset is being amortized over an eight-year period using the straight-line method.

We recorded amortization expense of $1.3 million the three months ended March 31, 2020 and three months ended March 31, 2019, respectively.

7. Accrued and other current liabilities

Accrued and other current liabilities consist of the following (in thousands):


	March 31,		December 31,

	2020		2019
Consulting and professional fees	$	5,640	$	4,335
Supply agreement - current portion		4,391		2,773
Accrued sales allowances		2,229		2,990
Employee compensation		2,078		4,452
Accrued taxes		1,892		1,892
Severance		1,088		2,968
Lease liability - current portion		384		374
Accrued royalties		302		806
Other		509		372
Total accrued liabilities	$	18,513	$	20,962

8. Commitments and contingencies

(a) Commitments to Taro Pharmaceuticals Industries Ltd.

In December 2016, we acquired the U.S. marketing rights to Keveyis (dichlorphenamide) from Taro. Under the terms of an Asset Purchase Agreement, we paid Taro an upfront payment in two installments of $1 million in December 2016 and $7.5 million in March 2017, and will pay an aggregate of $7.5 million in potential milestones upon the achievement of certain product sales targets. Taro has agreed to continue to manufacture Keveyis for us under an exclusive supply agreement through the orphan exclusivity period. We are obligated to purchase certain annual minimum amounts of product totaling approximately $29 million over a six-year period. As of March 31, 2020, our remaining obligation was $19.0 million. Our Supply Agreement with Taro may extend beyond the orphan exclusivity period unless terminated by either party pursuant to the terms of the agreement. If terminated by Taro at the conclusion of the orphan exclusivity period, we have the right to manufacture the product on our own or have the product manufactured by a third party on our behalf. We are also required to reimburse Taro for their royalty obligation resulting from their sale of Keveyis to us.

(b) Indemnifications

In the ordinary course of business and in connection with the sale of assets and businesses and other transactions, we often indemnify our counterparties against certain liabilities that may arise in connection with the transaction or that are related to events and activities prior to or following a transaction, such as breaches of contracts, unfavorable tax consequences and employee liabilities. If the indemnified party were to make a successful claim pursuant to the terms of the indemnification, we may be required to reimburse the loss and such amount could be material to our financial statements. Where appropriate, the obligation for such indemnifications is recorded as a liability. Because the amount of these types of indemnifications generally is not specifically stated, the overall maximum

Table of Contents

amount of the obligation under such indemnifications cannot be reasonably estimated. However, we believe that the likelihood of a material liability being triggered under these indemnification obligations is not probable at this time.

9. Income taxes

Deferred tax assets and liabilities are recognized for the future tax consequences of differences between the carrying amounts and tax bases of assets and liabilities and operating loss carryforwards and other attributes using enacted rates expected to be in effect when those differences reverse. Valuation allowances are provided against deferred tax assets that are not more likely than not to be realized.

We assess our ability to realize deferred tax assets. Changes in future earnings projections, among other factors, may cause us to adjust our valuation allowance on deferred tax assets. Any such adjustments would impact our income tax expense in the period in which it is determined that these factors have changed.

We did not incur income any tax expense for the three months ended March 31, 2020.

10. Warrants

Warrants

Our outstanding warrants as of March 31, 2020 are as follows:


							Warrants
							Outstanding
		Exercise		Expiration	Warrants	Warrants	March 31,
	Classification	Price		Date	Issued	Exercised	2020
Warrants in connection with private equity placement	Liability	$	2.50	6/28/2022	7,000,000	(1,970,000)	5,030,000
Warrants in connection with Horizon and Oxford loan agreement	Equity	$	2.45	12/28/2026	428,571	(267,857)	160,714
Warrants in connection with CRG loan agreement	Equity	$	7.37	7/14/2024	394,289	—	394,289
Warrants in connection with CRG loan amendment in January 2018	Equity	$	10.00	1/16/2025	1,248,250	—	1,248,250
					9,071,110		6,833,253

11. Stock‑based compensation

Our board of directors has adopted the 2017 Inducement Plan (the “Inducement Plan”). The Inducement Plan provides for the grant of equity-based awards to new employees. The purpose of the Inducement Plan is to attract valued employees by offering them a greater stake in our success and a closer identity with us, and to encourage ownership of our ordinary shares by such employees. The Inducement Plan became effective on February 23, 2017. As of March 31, 2020, 1,374,528 shares are available for issuance pursuant to the Inducement Plan.

Our board of directors has adopted, and our shareholders have approved, the 2015 Equity Compensation Plan (the “2015 Plan”). The 2015 Plan provides for the grant of incentive stock options to our employees and any parent or subsidiary corporation’s employees, and for the grant of nonstatutory stock options, stock awards, and RSUs to our employees, directors and consultants and our parent or subsidiary corporations’ employees and consultants. The 2015 Plan became effective on September 3, 2015. As of March 31, 2020, 561,158 shares are available for issuance pursuant to the 2015 Plan.

Our board of directors has adopted, and our shareholders have approved, the Non‑Employee Director Equity Compensation Plan (the “Non‑Employee Director Plan”). The Non‑Employee Director Plan provides for the grant of nonstatutory stock options, stock awards, and RSUs to our non‑employee directors. The Non‑Employee Director Plan

Table of Contents

became effective on September 3, 2015. As of March 31, 2020, 271,029 shares are available for issuance pursuant to the Non‑Employee Director Plan.

A summary of our outstanding stock options as of March 31, 2020 is as follows:


	Options Outstanding
				Weighted-
				Average
		Weighted-		Remaining
		Average		Contractual
	Number of	Exercise		Term	Aggregate
	Shares	Price		(Years)	Intrinsic Value
					(in thousands)
Outstanding—January 1, 2020	9,192,684	$	6.58	5.96	$	164
Granted	2,393,000	$	2.97
Forfeited and cancelled	(1,133,316)	$	10.66
Exercised	—	$	—
Outstanding—March 31, 2020	10,452,368	$	5.31	2.01	$	104
Vested and exercisable—March 31, 2020	5,100,335	$	6.86	5.39	$	6

Stock‑based compensation expense

We recognized stock‑based compensation expense for employees and directors for stock options and RSUs as follows (in thousands):


	Three Months Ended
	March 31,
	2020		2019
Selling, general and administrative	$	1,270	$	1,811
Research and development		481		512
Total stock-based compensation	$	1,751	$	2,323

As of March 31, 2020, the total unrecognized compensation expense related to unvested stock options is $12.4 million, which we expect to recognize over an estimated weighted‑average period of 2.89 years.

In determining the estimated fair value of our service-based awards, we use the Black‑Scholes option‑pricing model and assumptions discussed below. Each of these inputs is subjective and generally requires significant judgment. The fair value of our service-based awards that were granted during the years was estimated with the following assumptions:


	Three Months Ended
	March 31,
	2020	2019
Expected term (in years)	6.07	6.09
Risk-free interest rate	1.47%-1.48%	2.47%-2.61%
Expected volatility	78.15%-78.21%	80.00%-80.85%
Dividend rate	—%	—%

Restricted stock units

We grant RSUs to employees and to members of our board of directors. RSUs that are granted to employees vest two years from the date of issuance, provided that the employee is employed by us on such vesting date. RSUs that are granted to directors, vest on the one-year anniversary of the grant date, provided that the director continues to serve as a member of the board of directors continuously from the grant date through such one-year anniversary. All RSUs will

Table of Contents

fully vest upon a change of control of our company. If and when the RSUs vest, we will issue one ordinary share for each whole RSU that has vested, subject to satisfaction of the employee’s or director’s tax withholding obligations. The RSUs will cease to be outstanding upon the issuance of ordinary shares upon vesting. We recorded expense, which is included in the stock-based compensation table above, of $0.5 million for the three months ended March 31, 2020 and 2019, respectively. As of March 31, 2020, the total unrecognized compensation expense related to unvested RSUs is $1.6 million, which we expect to recognize over an estimated weighted‑average period of 1.21 years.

A summary of our unvested RSUs as of March 31, 2020 is as follows:


		Number of
		Shares
Outstanding—January 1, 2020		791,350
Granted		212,650
Forfeited		(17,200)
Vested		(61,000)
Unvested—March 31, 2020		925,800

ITEM 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion and analysis should be read in conjunction with our interim unaudited consolidated financial statements and related notes included elsewhere in this Quarterly Report on 10-Q (this “Quarterly Report”) and the audited financial statements and related notes for the year ended December 31, 2019 and related Management’s Discussion and Analysis of Financial Condition and Results of Operations that are included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2019 (the “2019 Annual Report”) filed with the Securities and Exchange Commission (“SEC”) on February 28, 2020. As used in this Quarterly Report, unless the context suggests otherwise, “we,” “us,” “our,” or “Strongbridge” refer to Strongbridge Biopharma plc.

Special Note Regarding Forward-Looking Statements

This Quarterly Report contains forward-looking statements that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this Quarterly Report, including statements regarding our strategy, future operations, future financial position, future revenue, projected costs, prospects, prospective products, size or market or patient population, plans, objectives of management, expected market growth and the anticipated effects of the coronavirus (COVID-19) pandemic on our business, operating results and financial condition are forward-looking statements. The words “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.

By their nature, forward-looking statements involve risks and uncertainties because they relate to events, competitive dynamics, and healthcare, regulatory and scientific developments and depend on the economic circumstances that may or may not occur in the future or may occur on longer or shorter timelines than anticipated. Although we believe that we have a reasonable basis for each forward-looking statement contained in this Quarterly Report, we caution you that forward-looking statements are not guarantees of future performance and that our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate may differ materially from the forward-looking statements contained in this Quarterly Report. In addition, even if our results of operations, financial condition and liquidity, and the development of the industry in which we operate are consistent with the forward-looking statements contained in this Quarterly Report, they may not be predictive of results or developments in future periods.

Table of Contents

Any forward-looking statement that we make in this Quarterly Report speaks only as of the date of such statement, and we undertake no obligation to update such statements to reflect events or circumstances after the date of this Quarterly Report except as required by law. You should also read carefully the factors described in the “Risk Factors” section of our 2019 Annual Report and this Quarterly Report to better understand the risks and uncertainties inherent in our business and underlying any forward-looking statements.

Overview

We are a global, commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs.

We have two clinical-stage product candidates for rare endocrine diseases, Recorlev and veldoreotide. Recorlev (levoketoconazole) is a cortisol synthesis inhibitor currently being studied for the treatment of endogenous Cushing's syndrome. Veldoreotide is a next-generation somatostatin analog being investigated for potential applications in conditions amenable to somatostatin receptor activation. Both levoketoconazole and veldoreotide have received orphan designation from the FDA and the European Medicines Agency (“EMA”).

Recent Developments

COVID-19 emerged in Asia at the end of calendar year 2019. On March 11, 2020 the World Health Organization declared COVID-19 a pandemic, and on March 13, 2020 the United States declared a national emergency with respect to COVID-19. The COVID-19 pandemic has negatively impacted the global economy, disrupted global supply chains and created significant volatility and disruption in the financial markets.

While the COVID-19 outbreak did not have a material impact on our business, financial condition or results of operations for the three months ended March 31, 2020, we have experienced business disruptions as a result of the outbreak. For example, all of our employees are currently working remotely from home, we have suspended all travel for business, and our field teams are no longer able to visit physicians.

We continue to monitor the impacts of COVID-19 on the global economy and on our business operations. However, at this time, it is difficult to predict how long the potential operational impacts of COVID-19 will remain in effect or to what degree they will impact our operations and financial results. An extended period of global supply chain and economic disruption could materially affect our business, results of operations, access to sources of liquidity and financial condition, as well as our ability to execute our business strategies and initiatives in their respective expected time frames.

Table of Contents

Financial Operations Overview

The following discussion sets forth certain components of our statements of operations as well as factors that impact those items.

Product Sales, net

Revenues from sales of our products are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established and that result from rebates, co-pay assistance and other allowances that are offered by us and the patients’ payors. These reserves are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to our customer) or a current liability (if the amount is payable to a party other than our customer). Where appropriate, these estimates may take into consideration a range of possible outcomes that are probability-weighted for relevant factors such as our historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. Overall, these reserves reflect our best estimates of the amount of consideration to which we are entitled based on the terms of the contract. For a complete discussion of accounting for net product revenue, see Note 3, "Revenue recognition" to our consolidated financial statements.

Cost of Sales

Cost of sales includes third-party acquisition costs, third-party warehousing and product distribution charges.

Selling, General and Administrative Expenses

Selling, general and administrative expenses include personnel costs, costs for outside professional services and other allocated expenses. Personnel costs consist of salaries, bonuses, benefits, travel and stock‑based compensation. Outside professional services consist of legal, accounting and audit services, commercial evaluation and strategy services, sales, market access, marketing, investor relations, public relations, recruiting and other consulting services.

Research and Development Expenses

We expense all research and development costs as incurred. Our research and development expenses consist primarily of costs incurred in connection with the development of our product candidates, including:

personnel‑related costs, such as salaries, bonuses, benefits, travel and other related expenses, including stock‑based compensation;

expenses incurred under our agreements with contract research organizations (CROs), clinical sites, contract laboratories, medical institutions and consultants that plan and conduct our preclinical studies and clinical trials. We recognize costs for each grant project, preclinical study or clinical trial that we conduct based on our evaluation of the progress to completion, including the use of information and data provided to us by our external research and development vendors and clinical sites;

costs associated with regulatory filings; and

costs of acquiring preclinical study and clinical trial materials, and costs associated with formulation, process development and statistical analysis.

We do not allocate personnel‑related research and development costs, including stock‑based compensation or other indirect costs, to specific programs, as they are deployed across multiple projects under development.

Table of Contents

Amortization of Intangible Asset

Amortization of intangible asset relates to the amortization of our product rights to Keveyis. This intangible asset is being amortized over an eight-year period using the straight-line method.

Other Income (Expense), Net

Other income (expense), net, consists of unrealized gain on the remeasurement of the fair value of warrant liability, interest income generated from our cash and cash equivalents, foreign exchange gains and losses and gains and losses on investments. In 2019, we recorded income and expenses relating to our service agreement with NNI to fund the costs of 23 of our field-based employees who provided full-time ongoing services to NNI, including the promotion of Macrilen in the United States.

Critical Accounting Policies and Significant Judgments and Estimates

This management’s discussion and analysis of our financial condition and results of operations is based on our consolidated financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”). The preparation of these consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as expenses incurred during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

We believe there have been no significant changes in our critical accounting policies and significant judgments and estimates as discussed in “Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations” of our 2019 Annual Report.

Table of Contents

Results of Operations

Comparison of the Three Months Ended March 31, 2020 and 2019.

The following table sets forth our results of operations for the three months ended March 31, 2020 and 2019.


	Three Months Ended
	March 31,				Change
	2020		2019		$
	(in thousands)
Revenues:
Net product sales	$	6,663	$	4,333	$	2,330
Royalty revenues		11		10		1
Total revenues		6,674		4,343		2,331

Cost and operating expenses:
Cost of sales (excluding amortization of intangible asset)	$	969	$	813	$	156
Selling, general and administrative		10,403		12,100		(1,697)
Research and development		7,552		6,583		969
Amortization of intangible asset		1,256		1,256		—
Total cost and expenses		20,180		20,752		(572)
Operating loss		(13,506)		(16,409)		2,903
Other income (expense), net		808		(1,348)		2,156
Loss before income taxes		(12,698)		(17,757)		5,059
Income tax expense		—		(677)		677
Net loss	$	(12,698)	$	(18,434)	$	5,736

Revenues

Net product sales were $6.7 million for the three months ended March 31, 2020, an increase of $2.3 million compared to the three months ended March 31, 2019. Product sales from Keveyis increased by $2.3 million, primarily due to growth in the number of patients on Keveyis and price.

Selling, General and Administrative Expenses

The following table summarizes our selling, general and administrative expenses during the three months ended March 31, 2020 and 2019:


	Three Months Ended
	March 31,				Change
	2020		2019		$
	(in thousands)
Compensation and other personnel costs	$	5,185	$	5,863	$	(678)
Outside professional and consulting services		3,780		4,160		(380)
Stock-based compensation expense		1,270		1,811		(541)
Facility costs		168		266		(98)
Total selling, general and administrative expenses	$	10,403	$	12,100	$	(1,697)

Selling, general and administrative expenses were $10.4 million for the three months ended March 31, 2020, a decrease of $1.7 million compared to the three months ended March 31, 2019. Outside professional and consulting services decreased $0.4 million during the three months ended March 31, 2020. Compensation and other personnel costs and stock compensation decreased $1.2 million due to reduced headcount in 2020.

Table of Contents

Research and Development Expenses

The following table summarizes our research and development expenses during the three months ended March 31, 2020 and 2019:


	Three Months Ended
	March 31,				Change
	2020		2019		$
	(in thousands)
Product development and supporting activities	$	5,537	$	4,735	$	802
Compensation and other personnel costs		1,534		1,336		198
Stock-based compensation expense		481		512		(31)
Total research and development expenses	$	7,552	$	6,583	$	969

Research and development expenses were $7.6 million for the three months ended March 31, 2020, an increase of $1.0 million compared to the three months ended March 31, 2019. The increase is due to increase product development and supporting activities for our LOGICS trial.

Amortization of Intangible Asset

Amortization of intangible asset was $1.3 million for the three months ended March 31, 2020 and 2019, respectively.

Other Income (Expense), Net

The following table summarizes our other income, net, during the three months ended March 31, 2020 and 2019:


	Three Months Ended
	March 31,				Change
	2020		2019		$
	(in thousands)
Unrealized gain (loss) on fair value of warrants	$	580	$	(1,820)	$	2,400
Income from field services agreement		—		2,016		(2,016)
Expense from field services agreement		—		(2,229)		2,229
Other income, net		228		685		(457)
Total other income (expense), net	$	808	$	(1,348)	$	2,156

Total other income (expense), net, increased by $2.2 million for the three months ended March 31, 2020 as compared to the three months ended March 31, 2019. The increase is largely due to a net $2.4 million increase in unrealized gain on fair value of warrants for the three months ended March 31, 2020.

Income Tax

We recorded no income tax expense for the three months ended March 31, 2020 as a result of recording full valuation allowances against our deferred tax asset and deferred tax liability.

Table of Contents

Cash Flows

Comparison for the Three Months Ended March 31, 2020 and 2019:


	Three Months Ended
	March 31
	2020		2019
	(in thousands)
Net cash (used in) provided by:
Operating activities	$	(15,240)	$	(18,308)
Investing activities		14,830		(15)
Financing activities		(68)		139
Net decrease in cash and cash equivalents	$	(478)	$	(18,184)

Operating Activities

Net cash used in operating activities was $15.2 million for the three months ended March 31, 2020 compared to $18.3 million for the three months ended March 31, 2019. The decrease in net cash used in operating activities resulted from an increase in total revenues of $2.3 million and reduced expenditures in our commercial activities for Keveyis.

Investing Activities

The increase in net cash provided by investing activities resulted from the maturities of our marketable securities.

Financing Activities

The decrease in net cash provided by financing activities was a result of the prior year amount including proceeds from stock option exercises, which were not present in the current period.

Liquidity and Capital Resources

We are continuously and critically reviewing our liquidity and anticipated capital requirements in light of our clinical trial activities and the significant uncertainty created by the COVID-19 global pandemic. However, we currently believe that our cash, cash equivalents and marketable securities of $62.8 million at March 31, 2020 will be sufficient to allow us to fund planned operations for at least 12 months beyond the issuance date of the unaudited consolidated financial statements included in this Quarterly Report.

Cash used to fund operating expenses is affected by the timing of when we are invoiced by our vendors, as reflected in the change in our outstanding accounts payable and accrued expenses set forth in the financial statements, included in this Quarterly Report.

Our future funding requirements will depend on many factors, including the following:

the amount of revenue that we receive from sales of Keveyis;

the cost and timing of establishing sales, marketing, distribution and administrative capabilities;

the scope, rate of progress, results and cost of our clinical trials testing and other related activities for Recorlev and veldoreotide and our ability to prepare and file our NDA submissions on a timely basis;

the number and characteristics of product candidates that we pursue, including any additional product candidates we may in‑license or acquire;

Table of Contents

the cost of filing, prosecuting, defending and enforcing our patent claims and other intellectual property rights;

the cost of defending potential intellectual property disputes, including patent infringement actions brought by third parties against us or our product candidates;

the cost, timing and outcomes of regulatory approvals, including product labeling;

adequate reimbursement from payors for Recorlev on a timely basis;

the terms and timing of any collaborative, licensing and other arrangements that we may establish, including any required milestone and royalty payments thereunder;

the emergence of competing technologies and their achieving commercial success before we do or other adverse market developments; and

any extended impact of COVID-19.

Off‑Balance Sheet Arrangements

We do not have variable interests in variable interest entities or any off‑balance sheet arrangements.

ITEM 3. Quantitative and Qualitative Disclosures about Market Risk

Except for the broad effects of COVID-19 including its negative impact on the global economy and major financial markets, there have been no material changes to our market risk exposures since December 31, 2019. In addition, as described in “Item 1A. Risk Factors,” there may be implications for our business with regard to the coronavirus, COVID-19.

ITEM 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our reports under the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and the rules and regulations thereunder, is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow for timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

Our management, under the supervision and with the participation of our principal executive officer and principal financial officer, evaluated the effectiveness of our disclosure controls and procedures as of March 31, 2020, the end of the period covered by this Quarterly Report. Based on that evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures as of March 31, 2020 were effective to provide reasonable assurance that the information required to be disclosed by us in reports filed or submitted under the

Table of Contents

Exchange Act, is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure.

Changes in Internal Control over Financial Reporting

We have begun remote working but this has not caused a material change in our internal control over financial reporting during the fiscal quarter ended March 31, 2020 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II – OTHER INFORMATION

ITEM 1. Legal Proceedings

The Company is not currently involved in any legal matters arising in the normal course of business. From time to time, the Company could become involved in disputes and various litigation matters that arise in the normal course of business. These may include disputes and lawsuits related to intellectual property, licensing, contract law and employee relations matters.

ITEM 1A. Risk Factors

The risks described in Item 1A. Risk Factors of our 2019 Annual Report could materially and adversely affect our business, financial condition and results of operations. The risk factors discussed in our 2019 Annual Report do not identify all risks that we face because our business operations could also be affected by additional factors that are not presently known to us or that we currently consider to be immaterial to our operations. The following is an update to our risk factors.

The current outbreak of the novel coronavirus, or COVID-19, or the future outbreak of any other highly infectious or contagious diseases, could materially and adversely affect our results of operations, financial condition and cash flows. Further, the spread of the COVID-19 outbreak has caused severe disruptions in the U.S. and global economy and financial markets and could potentially create widespread business continuity issues of an as yet unknown magnitude and duration.

In December 2019, a novel strain of coronavirus (COVID-19) was reported to have surfaced in Wuhan, China. COVID-19 has since spread to over 185 countries, including every state in the United States. On March 11, 2020 the World Health Organization declared COVID-19 a pandemic, and on March 13, 2020 the United States declared a national emergency with respect to COVID-19.

The outbreak of COVID-19 has severely impacted global economic activity and caused significant volatility and negative pressure in financial markets. The global impact of the outbreak has been rapidly evolving and many countries, including the United States, have reacted by instituting quarantines, mandating business and school closures and restricting travel, among other protective measures. Many experts predict that the outbreak will trigger a period of global economic slowdown or a global recession. COVID-19 or another pandemic could have material and adverse effects on our ability to successfully operate our business due to, among other factors:

a general decline in business activity;

the destabilization of the markets and negative impacts on the healthcare system globally could negatively impact our ability to market and sell Keveyis, including through the disruption of health care activities in general, the inability of our sales team to contact and/or visit doctors in person, patients’ interest in starting or

Table of Contents

staying on drugs, patients’ ability to obtain or maintain insurance coverage for Keveyis and our ability to support patients that presently use Keveyis;

difficulty accessing the capital and credit markets on favorable terms, or at all, and a severe disruption and instability in the global financial markets, or deteriorations in credit and financing conditions which could affect our access to capital necessary to fund business operations;

the potential negative impact on the health of our employees, especially if a significant number of them are impacted;

the potential negative impact on our clinical trials, including as a result of any difficulty enrolling new patients in our clinical trials during the outbreak and ensuring that patients already enrolled complete our clinical trials, as well the disruption of normal business activities at our CROs and any other potential trial delays caused by or related to COVID-19;

potential delays in the preparation and submission of applications for regulatory approval of our products, as well as potential delays in FDA’s ability to review applications in a timely manner consistent with past practices;

the potential negative impact on our ability to manufacture and distribute our products, including potential disruptions with third parties that manufacture and distribute products on our behalf; and

a deterioration in our ability to ensure business continuity during a disruption.

ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds

None

ITEM 3. Defaults Upon Senior Securities

None.

ITEM 4. Mine Safety Disclosures

Not applicable.

ITEM 5. Other Information

None.

Table of Contents

ITEM 6. Exhibits

EXHIBIT INDEX


10.1		Amendment to Executive Chairman Agreement by and among Strongbridge Biopharma plc, Strongbridge U.S. Inc. and John Johnson, dated as of April 8, 2020 (incorporated by reference to Exhibit 10.1 to the Form 8-K (File No. 001-37569) filed with the SEC on April 10, 2020)
31.1		Certificate of principal executive officer pursuant to Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2		Certificate of principal financial officer pursuant to Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1		Certificate of principal executive officer and principal financial officer pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS		XBRL Instance Document
101.SCH		XBRL Taxonomy Extension Schema Document
101.CAL		XBRL Taxonomy Extension Calculation Linkbase Document
101.LAB		XBRL Taxonomy Extension Label Linkbase Document
101.PRE		XBRL Taxonomy Extension Presentation Linkbase Document
101.DEF		XBRL Taxonomy Extension Definitions Linkbase Document

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.



	STRONGBRIDGE BIOPHARMA PLC

	By:		/s/ Robert Lutz
	Name:		Robert Lutz
	Title:		Chief Financial Officer

Date: May 6, 2020

EX-31.1 2 sbbp-20200331ex311d3af15.htm EX-31.1 sbbp_Exh_311

Exhibit 31.1

CERTIFICATIONS

I, John Johnson, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Strongbridge Biopharma plc;

2. Based on my knowledge, this Quarterly Report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this Quarterly Report;

4. I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such control over financial reporting, or caused such internal control over financial reporting to be designed under my supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes with generally accepted accounting principles;

c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report my conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.


Date: May 6, 2020

	By:	/s/ John Johnson
		John Johnson
		Executive Chairman
		(Principal Executive Officer)

EX-31.2 3 sbbp-20200331ex3120e48e6.htm EX-31.2 sbbp_Exh_312

Exhibit 31.2

CERTIFICATIONS

I, Robert Lutz, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Strongbridge Biopharma plc;

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.


Date: May 6, 2020

	By:	/s/ Robert Lutz
		Robert Lutz
		Chief Financial Officer
		(Principal Financial Officer)

EX-32.1 4 sbbp-20200331ex321f19183.htm EX-32.1 sbbp_Exh_321

Exhibit 32.1

CERTIFICATIONS PURSUANT TO 18 U.S.C. 1350

Pursuant to the requirement set forth in Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934, as amended, and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. § 1350), as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, John Johnson, the Executive Chairman (principal executive officer) of Strongbridge Biopharma plc (the “Company”), and Robert Lutz, the Chief Financial Officer (principal financial officer) of the Company, each hereby certifies that, to his knowledge on the date hereof:

(a) The Quarterly Report on Form 10-Q of the Company for the period ended March 31, 2020 filed on the date hereof with the Securities and Exchange Commission (the “Quarterly Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(b) The information contained in the Quarterly Report fairly presents, in all material respects, the financial condition and results of operations of the Company for the period covered by the Quarterly Report.

This certification shall not be deemed to be filed with the Securities and Exchange Commission and shall not be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Quarterly Report), irrespective of any general incorporation language contained in such filing. A signed original of this written statement required by Section 906 has been provided to the Company and will be retained and furnished to the Securities and Exchange Commission or its staff upon request.


	By:	/s/ John Johnson
		John Johnson
		Executive Chairman (Principal Executive Officer)
		May 6, 2020


	By:	/s/ Robert Lutz
		Robert Lutz
		Chief Financial Officer (Principal Financial Officer)
		May 6, 2020

EX-101.INS 5 sbbp-20200331.xml EX-101.INS 0001634432 srt:MaximumMember us-gaap:CommonStockMember 2020-01-01 2020-03-31 0001634432 srt:MaximumMember us-gaap:CommonStockMember 2019-01-01 2019-03-31 0001634432 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0001634432 us-gaap:RetainedEarningsMember 2020-03-31 0001634432 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001634432 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-03-31 0001634432 sbbp:DeferredSharesMember 2020-03-31 0001634432 us-gaap:RetainedEarningsMember 2019-12-31 0001634432 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001634432 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001634432 sbbp:DeferredSharesMember 2019-12-31 0001634432 us-gaap:RetainedEarningsMember 2019-03-31 0001634432 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0001634432 us-gaap:RetainedEarningsMember 2018-12-31 0001634432 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001634432 us-gaap:CommonStockMember 2020-03-31 0001634432 us-gaap:CommonStockMember 2019-12-31 0001634432 us-gaap:CommonStockMember 2019-03-31 0001634432 sbbp:DeferredSharesMember 2019-03-31 0001634432 us-gaap:CommonStockMember 2018-12-31 0001634432 sbbp:DeferredSharesMember 2018-12-31 0001634432 sbbp:NovoNordiskHealthcareAgMember us-gaap:CommonStockMember 2018-12-31 0001634432 2019-01-01 2019-12-31 0001634432 sbbp:NonEmployeeDirectorEquityCompensationPlanMember 2020-03-31 0001634432 sbbp:InducementPlan2017Member 2020-03-31 0001634432 sbbp:EquityCompensationPlan2015Member 2020-03-31 0001634432 us-gaap:RestrictedStockUnitsRSUMember 2019-12-31 0001634432 sbbp:EmployeeMember us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-03-31 0001634432 srt:DirectorMember us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-03-31 0001634432 us-gaap:RoyaltyMember 2020-01-01 2020-03-31 0001634432 us-gaap:ProductMember 2020-01-01 2020-03-31 0001634432 us-gaap:RoyaltyMember 2019-01-01 2019-03-31 0001634432 us-gaap:ProductMember 2019-01-01 2019-03-31 0001634432 sbbp:KeveyisMember sbbp:AcquiredDevelopedProductRightsMember 2017-03-01 2017-03-31 0001634432 us-gaap:AccountingStandardsUpdate201602Member 2019-01-01 2019-01-01 0001634432 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0001634432 us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0001634432 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0001634432 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001634432 2019-01-01 2019-01-01 0001634432 sbbp:KeveyisMember 2020-03-31 0001634432 sbbp:KeveyisMember 2019-12-31 0001634432 us-gaap:WarrantMember 2020-03-31 0001634432 us-gaap:WarrantMember 2019-12-31 0001634432 us-gaap:WarrantMember 2020-01-01 2020-03-31 0001634432 us-gaap:EmployeeStockOptionMember 2020-03-31 0001634432 us-gaap:RestrictedStockUnitsRSUMember 2020-03-31 0001634432 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-03-31 0001634432 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember sbbp:StrongbridgeIrelandLtdMember 2018-12-31 0001634432 sbbp:KeveyisMember sbbp:AcquiredDevelopedProductRightsMember 2020-03-31 0001634432 sbbp:WarrantsIssuedPrivateEquityPlacementFacilityMember 2020-03-31 0001634432 sbbp:WarrantsIssuedLoanAgreementOneMember 2020-03-31 0001634432 sbbp:WarrantsIssuedCrgCreditFacilityMember 2020-03-31 0001634432 sbbp:WarrantsIssuedCrgCreditFacilityAmendmentMember 2020-03-31 0001634432 us-gaap:AccountingStandardsUpdate201602Member 2019-01-01 0001634432 2019-03-31 0001634432 2018-12-31 0001634432 us-gaap:USTreasurySecuritiesMember 2020-03-31 0001634432 us-gaap:CommercialPaperMember 2020-03-31 0001634432 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-03-31 0001634432 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0001634432 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0001634432 us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0001634432 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001634432 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001634432 us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001634432 us-gaap:WarrantMember 2020-01-01 2020-03-31 0001634432 us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-03-31 0001634432 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-03-31 0001634432 us-gaap:WarrantMember 2019-01-01 2019-03-31 0001634432 us-gaap:RestrictedStockUnitsRSUMember 2019-01-01 2019-03-31 0001634432 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-03-31 0001634432 sbbp:KeveyisMember 2020-01-01 2020-03-31 0001634432 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2020-01-01 2020-03-31 0001634432 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-03-31 0001634432 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2019-01-01 2019-03-31 0001634432 us-gaap:RestrictedStockUnitsRSUMember 2019-01-01 2019-03-31 0001634432 us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-03-31 0001634432 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001634432 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-03-31 0001634432 sbbp:WarrantsIssuedCrgCreditFacilityMember 2020-01-01 2020-03-31 0001634432 sbbp:WarrantsIssuedCrgCreditFacilityAmendmentMember 2020-01-01 2020-03-31 0001634432 sbbp:WarrantsIssuedPrivateEquityPlacementFacilityMember 2020-01-01 2020-03-31 0001634432 sbbp:WarrantsIssuedLoanAgreementOneMember 2020-01-01 2020-03-31 0001634432 us-gaap:CommonStockMember 2019-01-01 2019-03-31 0001634432 sbbp:NovoNordiskHealthcareAgMember us-gaap:CommonStockMember 2018-12-01 2018-12-31 0001634432 us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-03-31 0001634432 srt:MaximumMember 2020-01-01 2020-03-31 0001634432 sbbp:NovoNordiskHealthcareAgMember 2019-12-01 2019-12-31 0001634432 sbbp:NovoNordiskIncMember sbbp:ServicesAgreementMember 2018-12-01 2018-12-31 0001634432 2019-01-01 2019-03-31 0001634432 sbbp:KeveyisMember sbbp:AcquiredDevelopedProductRightsMember 2016-12-01 2016-12-31 0001634432 sbbp:KeveyisMember sbbp:AcquiredDevelopedProductRightsMember 2016-12-31 0001634432 2020-03-31 0001634432 2019-12-31 0001634432 2020-05-01 0001634432 2020-01-01 2020-03-31 sbbp:segment sbbp:product xbrli:pure sbbp:customer sbbp:installment sbbp:employee iso4217:USD xbrli:shares iso4217:USD xbrli:shares false --12-31 Q1 2020 2020-03-31 10-Q 0001634432 54247501 Yes true true Accelerated Filer Yes STRONGBRIDGE BIOPHARMA plc false true -48000 20962000 18513000 2773000 4391000 15947000 11556000 2990000 2229000 2968000 1088000 2400000 7500000 P6Y 1.098 1.098 40000 40000 40000 40000 40000 40000 44000 44000 <div> <div> Leases We account for leases in accordance with Accounting Standards Codification Topic 842, Leases, (“ASC 842”). We determine if an arrangement is a lease at contract inception. A lease exists when a contract conveys to us the right to control the use of identified property, plant, or equipment for a period of time in exchange for consideration. The definition of a lease embodies two conditions: (1) there is an identified asset in the contract that is land or a depreciable asset (i.e., property, plant, and equipment), and (2) we have the right to control the use of the identified asset. Operating leases where we are the lessee are included in Right of use (“ROU”) assets and Other current liabilities and Other long-term liabilities on our Consolidated Balance Sheets. The lease liabilities are initially and subsequently measured at the present value of the unpaid lease payments at the lease commencement date. Key estimates and judgments include how we determined (1) the discount rate we use to discount the unpaid lease payments to present value, (2) lease term and (3) lease payments. ASC 842 requires a lessee to discount its unpaid lease payments using the interest rate implicit in the lease or, if that rate cannot be readily determined, its incremental borrowing rate. Because our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. Our incremental borrowing rate for a lease is the rate of interest we would have to pay on a collateralized basis to borrow an amount equal to the lease payments under similar terms. The lease term for all of our leases includes the noncancellable period of the lease. Lease payments included in the measurement of the lease asset or liability are comprised of our fixed payments. The ROU asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for lease payments made at or before the lease commencement date less any lease incentives received. For operating leases, the ROU asset is subsequently measured throughout the lease term at the carrying amount of the lease liability, plus (minus) any prepaid (accrued) lease payments, less the unamortized balance of lease incentives received. Lease expense for lease payments is recognized on a straight-line basis over the lease term. We monitor for events or changes in circumstances that require a reassessment of a lease. If a reassessment results in the remeasurement of a lease liability, a corresponding adjustment is made to the carrying amount of the corresponding ROU asset unless doing so would reduce the carrying amount of the ROU asset to an amount less than zero. In that case, the amount of the adjustment that would result in a negative ROU asset balance is recorded in profit or loss. We have elected not to recognize ROU assets and lease liabilities for all short-term leases that have a lease term of 12 months or less. We recognize the lease payments associated with our short-term leases as an expense on a straight-line basis over the lease term. Variable lease payments associated with these leases are recognized and presented in the same manner as for all our other leases. We adopted ASC 842 using a modified retrospective transition approach as of the effective date, as permitted by the amendments in ASU 2018-11. As a result, we were not required to adjust our comparative period financial information for effects of the standard or make the new required lease disclosures for periods before the date of adoption (i.e., January 1, 2019). We have elected to adopt the package of transition practical expedients and, therefore, have not reassessed (1) whether existing or expired contracts contain a lease, (2) lease classification for existing or expired leases or (3) the accounting for initial direct costs that were previously capitalized. We did not elect the practical expedient to use hindsight for leases existing at the adoption date. Further, we do not expect the amendments in ASU 2018-01: Land Easement Practical Expedient to have an effect on us because we do not enter into land easement arrangements. <div /></div> </div> 3000 2229000 2016000 23 2 2 1 0.7 6000000 2 P12M <div> <div> 3. Revenue recognition Product sales, net We sell Keveyis to one specialty pharmacy provider (the “Customer”), who is the exclusive distributor of Keveyis in the United States.  The Customer subsequently resells Keveyis to patients, most of whom are covered by payors that may provide for government-mandated or privately negotiated rebates with respect to the purchase of Keveyis.  Revenues from sales of Keveyis are recognized when we satisfy a performance obligation by transferring control of the product to the Customer. Transfer of control occurs upon receipt of the product by the Customer.  We expense incremental costs related to the set-up of contracts with the Customer when incurred, as these costs do not meet the criteria for capitalization. Reserves for variable consideration   Revenues from sales of Keveyis are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established and that result from rebates, co-pay assistance and other allowances that are offered between us and the patients’ payors.  There is no variable consideration reserve for returns as we do not accept returns of Keveyis.  These reserves are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to the Customer) or a current liability (if the amount is payable to a party other than the Customer). Where appropriate, these estimates may take into consideration a range of possible outcomes that are probability-weighted for relevant factors such as our historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. Overall, these reserves reflect our best estimates of the amount of consideration to which we are entitled based on the terms of the contract. The amount of variable consideration that is included in the transaction price may be constrained, and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. Actual amounts of consideration ultimately received may differ from our estimates. We reassess our estimates on an ongoing basis. If actual results in the future vary from our estimates, we will adjust our estimates. Any such adjustments would affect net product revenue and earnings in the period such variances become known. Trade Discount: We provide the Customer with a discount that is explicitly stated in our contract and is recorded as a reduction of revenue in the period the related product revenue is recognized. In addition, we receive sales order management, data and distribution services from the Customer. To the extent the services received are distinct from our sale of Keveyis to the Customer, these payments are classified in selling, general and administrative expenses in our consolidated statement of operations and comprehensive loss. Funded Co-pay Assistance Program: We contract with a third-party to manage the co-pay assistance program intended to provide financial assistance to qualified insured patients. The calculation of the accrual for co-pay assistance is based on an estimate of claims and the cost per claim that we expect to receive associated with Keveyis that has been recognized as revenue, but remains in the distribution channel inventories at the end of each reporting period. These payments are consideration payable to the Customer and the related reserve is recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability which is included in accrued expenses on the consolidated balance sheet. Government Rebates: We are subject to discount obligations under state Medicaid programs and Medicare. We estimate our Medicaid and Medicare rebates for the estimated patient mix. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability, which is included in accrued expenses on the consolidated balance sheet. For Medicaid, accruals are based on estimates of future Medicaid beneficiary utilization applied to the Medicaid unit rebate formula established by the Center for Medicaid and Medicare Services. Effective January 1, 2019, manufacturers of pharmaceutical products are responsible for 70% of the patient’s cost of branded prescription drugs related to the Medicare Part D Coverage Gap. In order to estimate the cost to us of this Medicare coverage gap responsibility, we estimate the number of patients in the prescription drug coverage gap for whom we will owe an additional liability under the Medicare Part D program. Our liability for these rebates consists of estimates of claims for the current quarter and estimated future claims that will be made for Keveyis that have been recognized as revenue, but remains in the distribution channel inventories at the end of each reporting period. Temporary Supply and Patient Assistance Programs: We provide free Keveyis to uninsured patients who satisfy pre-established criteria for either the Temporary Supply Program or the Patient Assistance Program.  Patients who meet the Temporary Supply Program eligibility criteria may receive a temporary supply of free Keveyis for no more than sixty days while there is a determination of the patient’s third-party insurance, prescription drug benefit or other third-party coverage for Keveyis.  The Patient Assistance Program provides free Keveyis for up to twelve months to uninsured patients who satisfy pre-established criteria for financial need.  We do not recognize any revenue related to these free products and the associated costs are classified in selling, general and administrative expenses in our consolidated statements of operations and comprehensive loss. <div /></div> </div> P60D 1 5200000 39728 29300000 P3Y 267857 1970000 9071110 1248250 394289 428571 7000000 <div> <div> 10. Warrants Warrants Our outstanding warrants as of March 31, 2020 are as follows: <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:32.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:05.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:32.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:05.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Warrants </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:32.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:05.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Outstanding </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:32.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Exercise </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Expiration </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Warrants </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Warrants </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> March 31,  </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:32.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Classification </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Price </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Date </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Issued </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Exercised </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2020 </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:32.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Warrants in connection with private equity placement </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">      </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Liability </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">      </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2.50 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">      </td> <td valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 6/28/2022 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">      </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 7,000,000 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (1,970,000) </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 5,030,000 </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:32.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Warrants in connection with Horizon and Oxford loan agreement </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Equity </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2.45 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 12/28/2026 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 428,571 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (267,857) </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 160,714 </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:32.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Warrants in connection with CRG loan agreement </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Equity </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 7.37 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 7/14/2024 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 394,289 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 394,289 </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:32.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Warrants in connection with CRG loan amendment in January 2018 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Equity </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 10.00 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 1/16/2025 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 1,248,250 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 1,248,250 </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:32.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:05.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 9,071,110 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 6,833,253 </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   <div /></div> </div>

3331000

5285000

2289000

2690000

20962000

18513000

4335000

5640000

806000

302000

3000

6000

332085000

333768000

2323000

1751000

2323000

512000

500000

1811000

1751000

481000

500000

1270000

1300000

1256000

1300000

1256000

10205851

758850

6833253

10334368

925800

1803253

117638000

101060000

83543000

67958000

77616000

56544000

21072000

62371000

56078000

6293000

3000

21072000

6293000

3293000

6293000

3000000

6293000

57032000

56554000

56544000

56078000

<div> <div> Cash, cash equivalents and marketable securities We consider all short‑term highly liquid investments with an original maturity at the date of purchase of three months or less to be cash equivalents. Cash and cash equivalents consist of account balances at banks and money market accounts, respectively. <div /></div> </div>

62800000

122490000

104306000

57032000

56554000

-18184000

-478000

true

Modified Retrospective

10.00

7.37

2.45

2.50

6833253

1248250

394289

160714

5030000

<div> <div> 8. Commitments and contingencies <a name="_Hlk14874300"></a>(a) Commitments to Taro Pharmaceuticals Industries Ltd. In December 2016, we acquired the U.S. marketing rights to Keveyis (dichlorphenamide) from Taro. Under the terms of an Asset Purchase Agreement, we paid Taro an upfront payment in two installments of $1 million in December 2016 and $7.5 million in March 2017, and will pay an aggregate of $7.5 million in potential milestones upon the achievement of certain product sales targets. Taro has agreed to continue to manufacture Keveyis for us under an exclusive supply agreement through the orphan exclusivity period. We are obligated to purchase certain annual minimum amounts of product totaling approximately $29 million over a six-year period. As of March 31, 2020, our remaining obligation was $19.0 million. Our Supply Agreement with Taro may extend beyond the orphan exclusivity period unless terminated by either party pursuant to the terms of the agreement. If terminated by Taro at the conclusion of the orphan exclusivity period, we have the right to manufacture the product on our own or have the product manufactured by a third party on our behalf. We are also required to reimburse Taro for their royalty obligation resulting from their sale of Keveyis to us. (b) Indemnifications In the ordinary course of business and in connection with the sale of assets and businesses and other transactions, we often indemnify our counterparties against certain liabilities that may arise in connection with the transaction or that are related to events and activities prior to or following a transaction, such as breaches of contracts, unfavorable tax consequences and employee liabilities. If the indemnified party were to make a successful claim pursuant to the terms of the indemnification, we may be required to reimburse the loss and such amount could be material to our financial statements. Where appropriate, the obligation for such indemnifications is recorded as a liability. Because the amount of these types of indemnifications generally is not specifically stated, the overall maximum amount of the obligation under such indemnifications cannot be reasonably estimated. However, we believe that the likelihood of a material liability being triggered under these indemnification obligations is not probable at this time. <div /></div> </div>

0.01

600000000

54205852

54247501

54205852

54247501

542000

-18434000

-12695000

19000000

813000

969000

20752000

20180000

6000

6287000

3293000

2994000

<div> <div> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:39.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:16.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:19.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:16.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:39.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="8" valign="bottom" style="width:59.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> As of March 31, 2020 </td> </tr> <tr> <td valign="bottom" style="width:39.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:17.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Amortized Cost </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:20.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Net Unrealized Gain </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:17.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Fair Value </td> </tr> <tr> <td valign="bottom" style="width:39.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Commercial paper </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:16.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3,293 </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:19.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:16.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3,293 </td> </tr> <tr> <td valign="bottom" style="width:39.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> U.S. treasury securities </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:16.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2,994 </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:19.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  6 </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:16.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 3,000 </td> </tr> <tr> <td valign="bottom" style="width:39.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Total marketable securities </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:16.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 6,287 </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:19.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  6 </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:16.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 6,293 </td> </tr> </table></div>   <div /></div> </div>

18000

21000

<div> <div> 11. Stock‑based compensation Our board of directors has adopted the 2017 Inducement Plan (the “Inducement Plan”). The Inducement Plan provides for the grant of equity-based awards to new employees. The purpose of the Inducement Plan is to attract valued employees by offering them a greater stake in our success and a closer identity with us, and to encourage ownership of our ordinary shares by such employees. The Inducement Plan became effective on February 23, 2017. As of March 31, 2020, 1,374,528 shares are available for issuance pursuant to the Inducement Plan. Our board of directors has adopted, and our shareholders have approved, the 2015 Equity Compensation Plan (the “2015 Plan”). The 2015 Plan provides for the grant of incentive stock options to our employees and any parent or subsidiary corporation’s employees, and for the grant of nonstatutory stock options, stock awards, and RSUs to our employees, directors and consultants and our parent or subsidiary corporations’ employees and consultants. The 2015 Plan became effective on September 3, 2015.  As of March 31, 2020, 561,158 shares are available for issuance pursuant to the 2015 Plan. Our board of directors has adopted, and our shareholders have approved, the Non‑Employee Director Equity Compensation Plan (the “Non‑Employee Director Plan”). The Non‑Employee Director Plan provides for the grant of nonstatutory stock options, stock awards, and RSUs to our non‑employee directors. The Non‑Employee Director Plan became effective on September 3, 2015.  As of March 31, 2020, 271,029 shares are available for issuance pursuant to the Non‑Employee Director Plan. A summary of our outstanding stock options as of March 31, 2020 is as follows: <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:56.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:06.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:56.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="9" valign="bottom" style="width:41.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Options Outstanding </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:56.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:10.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:01.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:06.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Weighted- </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:56.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:10.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:06.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Average </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:56.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:10.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Weighted- </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Remaining </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:56.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:10.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Average </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Contractual </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:56.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:10.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Number of </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Exercise </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Term </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Aggregate </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:56.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:10.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Shares </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Price </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (Years) </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Intrinsic Value </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:56.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:10.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:06.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (in thousands) </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:56.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Outstanding—January 1, 2020 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 9,192,684 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 6.58 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 5.96 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 164 </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:56.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Granted </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2,393,000 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2.97 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:56.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Forfeited and cancelled </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (1,133,316) </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 10.66 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:56.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Exercised </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:56.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Outstanding—March 31, 2020 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 10,452,368 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 5.31 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2.01 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 104 </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:56.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Vested and exercisable—March 31, 2020 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 5,100,335 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 6.86 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 5.39 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  6 </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> </table></div>   Stock‑based compensation expense We recognized stock‑based compensation expense for employees and directors for stock options and RSUs as follows (in thousands): <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:71.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:71.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:26.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Three Months Ended </td> </tr> <tr> <td valign="bottom" style="width:71.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="5" valign="bottom" style="width:26.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> March 31,  </td> </tr> <tr> <td valign="bottom" style="width:71.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2020 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:12.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2019 </td> </tr> <tr> <td valign="bottom" style="width:71.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Selling, general and administrative </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,270 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,811 </td> </tr> <tr> <td valign="bottom" style="width:71.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Research and development </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 481 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 512 </td> </tr> <tr> <td valign="bottom" style="width:71.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Total stock-based compensation </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,751 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2,323 </td> </tr> </table></div> As of March 31, 2020, the total unrecognized compensation expense related to unvested stock options is $12.4 million, which we expect to recognize over an estimated weighted‑average period of 2.89 years. In determining the estimated fair value of our service-based awards, we use the Black‑Scholes option‑pricing model and assumptions discussed below. Each of these inputs is subjective and generally requires significant judgment. The fair value of our service-based awards that were granted during the years was estimated with the following assumptions: <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 81.16%;"> <tr> <td valign="bottom" style="width:61.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:16.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:61.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="3" valign="bottom" style="width:35.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Three Months Ended </td> <td valign="bottom" style="width:00.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:61.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="3" valign="bottom" style="width:35.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> March 31,  </td> <td valign="bottom" style="width:00.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:61.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">       </td> <td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2020 </td> <td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">       </td> <td valign="bottom" style="width:16.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2019 </td> <td valign="bottom" style="width:00.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:61.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Expected term (in years) </td> <td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 6.07 </td> <td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:16.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 6.09 </td> <td valign="bottom" style="width:00.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:61.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Risk-free interest rate </td> <td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 1.47%-1.48% </td> <td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:16.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2.47%-2.61% </td> <td valign="bottom" style="width:00.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:61.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Expected volatility </td> <td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 78.15%-78.21% </td> <td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:16.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 80.00%-80.85% </td> <td valign="bottom" style="width:00.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:61.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Dividend rate </td> <td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> —% </td> <td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:16.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> —% </td> <td valign="bottom" style="width:00.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> </table></div>   Restricted stock units We grant RSUs to employees and to members of our board of directors.  RSUs that are granted to employees vest two years from the date of issuance, provided that the employee is employed by us on such vesting date. RSUs that are granted to directors, vest on the one-year anniversary of the grant date, provided that the director continues to serve as a member of the board of directors continuously from the grant date through such one-year anniversary. All RSUs will fully vest upon a change of control of our company.  If and when the RSUs vest, we will issue one ordinary share for each whole RSU that has vested, subject to satisfaction of the employee’s or director’s tax withholding obligations. The RSUs will cease to be outstanding upon the issuance of ordinary shares upon vesting. We recorded expense, which is included in the stock-based compensation table above, of $0.5 million for the three months ended March 31, 2020 and 2019, respectively. As of March 31, 2020, the total unrecognized compensation expense related to unvested RSUs is $1.6 million, which we expect to recognize over an estimated weighted‑average period of 1.21 years. A summary of our unvested RSUs as of March 31, 2020 is as follows: <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 79.62%;"> <tr> <td valign="bottom" style="width:78.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:18.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:78.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:18.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Number of </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:78.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:18.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Shares </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:78.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Outstanding—January 1, 2020 </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:18.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 791,350 </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:78.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Granted </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:18.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 212,650 </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:78.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Forfeited </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:18.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (17,200) </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:78.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Vested </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:18.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (61,000) </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:78.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Unvested—March 31, 2020 </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:18.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 925,800 </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   <div /></div> </div>

145000000

-0.34

-0.23

-0.34

-0.24

4452000

2078000

P2Y10M21D

P1Y2M16D

1600000

12400000

1820000

-580000

<div> <div> The following table presents our assets and liabilities that are measured at fair value on a recurring basis for the periods presented (in thousands): <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:33.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:13.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:14.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:33.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="11" valign="bottom" style="width:64.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> As of March 31, 2020 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:33.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:15.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Level I </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:15.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Level II </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:15.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Level III </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:15.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Total </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:33.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:8.50pt;padding:0pt;"> Cash equivalents </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:8.50pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:8.50pt;padding:0pt;">   </td> <td valign="bottom" style="width:13.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:8.50pt;padding:0pt;"> 56,078 </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:8.50pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:8.50pt;padding:0pt;">   </td> <td valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:8.50pt;padding:0pt;">  — </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:8.50pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:8.50pt;padding:0pt;">   </td> <td valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:8.50pt;padding:0pt;">  — </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:8.50pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:8.50pt;padding:0pt;">   </td> <td valign="bottom" style="width:14.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:8.50pt;padding:0pt;"> 56,078 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:8.50pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:33.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Marketable securities </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:13.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> — </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6,293 </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> — </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:14.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6,293 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:33.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Total assets </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:13.74%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 56,078 </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:13.82%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 6,293 </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:13.82%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:14.24%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>62,371 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:33.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Warrant liability </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:13.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> — </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,547 </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:14.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 3,547 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:33.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Total liabilities </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:13.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3,547 </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:14.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,547 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:33.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:13.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:33.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="11" valign="bottom" style="width:64.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> As of December 31, 2019 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:33.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:15.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Level I </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:15.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Level II </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:15.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Level III </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:15.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Total </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:33.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Cash equivalents </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 56,544 </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:13.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 56,544 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:33.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Marketable securities </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 21,072 </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:13.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 21,072 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:33.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Total assets </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 56,544 </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 21,072 </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:13.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 77,616 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:33.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Warrant liability </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> — </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 4,127 </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:13.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 4,127 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:33.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Total liabilities </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 4,127 </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:13.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 4,127 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   <div /></div> </div>

<div> <div> 4. Fair value measurement We follow FASB accounting guidance on fair value measurements for financial assets and liabilities measured on a recurring basis. Because of their short-term nature, the amounts reported in the balance sheet for cash and accounts payable approximate fair value. The guidance requires fair value measurements to maximize the use of “observable inputs.” The three-level hierarchy of inputs to measure fair value are as follows:  Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities. Because of their short-term nature, the amounts reported in the balance sheet for cash and accounts payable approximate fair value. Level 2: Significant observable inputs other than Level 1 prices such as quoted prices in markets that are not active, or inputs that are observable, either directly or indirectly, for substantially the full term of the asset or liability Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity). The fair values of the outstanding warrants were measured using the Black-Scholes option-pricing model. Inputs used to determine estimated fair value of the warrant liabilities include the estimated fair value of the underlying stock at the valuation date, the estimated term of the warrants, risk-free interest rates, and the expected volatility of the underlying stock. The significant unobservable inputs used in the fair value measurement of the warrant liabilities were the volatility rate and the estimated term of the warrants. Generally, increases (decreases) in the fair value of the underlying stock and estimated term would result in a directionally similar impact to the fair value measurement. We did not have any transfers between the different levels. The following table presents our assets and liabilities that are measured at fair value on a recurring basis for the periods presented (in thousands): <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:33.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:13.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:14.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:33.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="11" valign="bottom" style="width:64.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> As of March 31, 2020 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:33.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:15.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Level I </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:15.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Level II </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:15.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Level III </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:15.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Total </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:33.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:8.50pt;padding:0pt;"> Cash equivalents </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:8.50pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:8.50pt;padding:0pt;">   </td> <td valign="bottom" style="width:13.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:8.50pt;padding:0pt;"> 56,078 </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:8.50pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:8.50pt;padding:0pt;">   </td> <td valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:8.50pt;padding:0pt;">  — </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:8.50pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:8.50pt;padding:0pt;">   </td> <td valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:8.50pt;padding:0pt;">  — </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:8.50pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:8.50pt;padding:0pt;">   </td> <td valign="bottom" style="width:14.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:8.50pt;padding:0pt;"> 56,078 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:8.50pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:33.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Marketable securities </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:13.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> — </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6,293 </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> — </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:14.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6,293 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:33.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Total assets </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:13.74%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 56,078 </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:13.82%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 6,293 </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:13.82%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:14.24%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>62,371 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:33.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Warrant liability </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:13.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> — </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,547 </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:14.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 3,547 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:33.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Total liabilities </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:13.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3,547 </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:14.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,547 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:33.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:13.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:33.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="11" valign="bottom" style="width:64.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> As of December 31, 2019 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:33.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:15.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Level I </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:15.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Level II </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:15.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Level III </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:15.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Total </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:33.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Cash equivalents </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 56,544 </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:13.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 56,544 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:33.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Marketable securities </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 21,072 </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:13.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 21,072 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:33.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Total assets </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 56,544 </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 21,072 </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:13.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 77,616 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:33.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Warrant liability </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> — </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 4,127 </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:13.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 4,127 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:33.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Total liabilities </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:13.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 4,127 </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:13.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 4,127 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   The following table presents a reconciliation of our level 3 warrant liability (in thousands): <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 85.22%;"> <tr> <td valign="bottom" style="width:78.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:17.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:78.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:17.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> As of March 31, 2020 </td> </tr> <tr> <td valign="bottom" style="width:78.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Balance as of December 31, 2019 </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="top" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:17.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 4,127 </td> </tr> <tr> <td valign="bottom" style="width:78.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Unrealized gain on fair value of warrants for three months ended March 31, 2020 </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="top" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:17.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (580) </td> </tr> <tr> <td valign="bottom" style="width:78.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Balance as of March 31, 2020 </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="top" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:17.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3,547 </td> </tr> </table></div>   <div /></div> </div>

<div> <div> The following table presents a reconciliation of our level 3 warrant liability (in thousands): <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 85.22%;"> <tr> <td valign="bottom" style="width:78.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:17.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:78.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:17.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> As of March 31, 2020 </td> </tr> <tr> <td valign="bottom" style="width:78.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Balance as of December 31, 2019 </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="top" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:17.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 4,127 </td> </tr> <tr> <td valign="bottom" style="width:78.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Unrealized gain on fair value of warrants for three months ended March 31, 2020 </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="top" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:17.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (580) </td> </tr> <tr> <td valign="bottom" style="width:78.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Balance as of March 31, 2020 </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="top" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:17.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3,547 </td> </tr> </table></div>   <div /></div> </div>

580000

4127000

3547000

40200000

25110000

23855000

P8Y

7256000

-17757000

-12698000

<div> <div> 9. Income taxes  Deferred tax assets and liabilities are recognized for the future tax consequences of differences between the carrying amounts and tax bases of assets and liabilities and operating loss carryforwards and other attributes using enacted rates expected to be in effect when those differences reverse. Valuation allowances are provided against deferred tax assets that are not more likely than not to be realized. We assess our ability to realize deferred tax assets. Changes in future earnings projections, among other factors, may cause us to adjust our valuation allowance on deferred tax assets. Any such adjustments would impact our income tax expense in the period in which it is determined that these factors have changed. We did not incur income any tax expense for the three months ended March 31, 2020. <div /></div> </div>

677000

539000

1954000

2290000

401000

-3191000

-6941000

649000

-101000

1210000

-266000

-1510000

-79000

25110000

23855000

32366000

31111000

1993000

1343000

<div> <div> 5. Marketable securities Marketable securities consist of the following: <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:39.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:16.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:19.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:16.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:39.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="8" valign="bottom" style="width:59.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> As of March 31, 2020 </td> </tr> <tr> <td valign="bottom" style="width:39.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:17.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Amortized Cost </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:20.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Net Unrealized Gain </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:17.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Fair Value </td> </tr> <tr> <td valign="bottom" style="width:39.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Commercial paper </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:16.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3,293 </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:19.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:16.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3,293 </td> </tr> <tr> <td valign="bottom" style="width:39.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> U.S. treasury securities </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:16.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2,994 </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:19.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  6 </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:16.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 3,000 </td> </tr> <tr> <td valign="bottom" style="width:39.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Total marketable securities </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:16.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 6,287 </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:19.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  6 </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:16.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 6,293 </td> </tr> </table></div>   <div /></div> </div>

true

false

45447000

39881000

117638000

101060000

24293000

23798000

4127000

3547000

<div> <div> We invest our excess cash balances in marketable securities of highly rated financial institutions.  We seek to diversify our investments and limit the amount of investment concentrations for individual institutions, maturities and investment types. We classify marketable debt securities as available-for-sale and, accordingly, record such securities at fair value. We classify these securities as current assets as these investments are intended to be available to us for use in funding current operations. There were no marketable securities with a maturity of greater than one year as of March 31, 2020. Unrealized gains and losses on marketable debt securities are recorded as a separate component of accumulated other comprehensive income (loss) included in stockholders’ equity. <div /></div> </div>

139000

-68000

-15000

14830000

-18308000

-15240000

-18434000

-12698000

-18434000

-12698000

-18434000

-13278000

true

<div> <div> Recent accounting pronouncements – not yet adopted In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments. ASU 2016-13 requires an entity to measure and recognize expected credit losses for certain financial instruments, including trade receivables, as an allowance that reflects the entity's current estimate of credit losses expected to be incurred. For available-for-sale debt securities with unrealized losses, the standard requires allowances to be recorded through net income instead of directly reducing the amortized cost of the investment under the current other-than-temporary impairment model. The standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019 for SEC filers, excluding smaller reporting companies, who have until fiscal years beginning after December 15, 2022. We do not expect the adoption of this standard to have a significant impact on our financial statements or internal controls. <div /></div> </div>

-1348000

808000

-16409000

-13506000

374000

384000

us-gaap:OtherLiabilitiesCurrent us-gaap:OtherLiabilitiesNoncurrent

789000

744000

<div> <div> 2. Summary of significant accounting policies and basis of presentation Basis of presentation These unaudited consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States (“U.S. GAAP”). The unaudited consolidated financial statements reflect all adjustments, which include only normal recurring adjustments that are, in the opinion of management, necessary to present a fair statement of the operating results and financial position for the periods presented. The preparation of the unaudited consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect reported amounts and disclosures in the consolidated financial statements.  Actual results could differ from those estimates. Results for the three months ended March 31, 2020 are not necessarily indicative of the results that may be expected for the year ending December 31, 2020. These unaudited consolidated financial statements should be read in conjunction with the accounting policies and notes to the audited consolidated financial statements included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2019 filed with the U.S. Securities and Exchange Commission on February 28, 2020 (the “2019 Annual Report”). Our significant accounting policies are described in Note 2 of the notes to the audited consolidated financial statements included in our 2019 Annual Report. Since the date of those financial statements, there have been no changes to our significant accounting policies. Leases We account for leases in accordance with Accounting Standards Codification Topic 842, Leases, (“ASC 842”). We determine if an arrangement is a lease at contract inception. A lease exists when a contract conveys to us the right to control the use of identified property, plant, or equipment for a period of time in exchange for consideration. The definition of a lease embodies two conditions: (1) there is an identified asset in the contract that is land or a depreciable asset (i.e., property, plant, and equipment), and (2) we have the right to control the use of the identified asset. Operating leases where we are the lessee are included in Right of use (“ROU”) assets and Other current liabilities and Other long-term liabilities on our Consolidated Balance Sheets. The lease liabilities are initially and subsequently measured at the present value of the unpaid lease payments at the lease commencement date. Key estimates and judgments include how we determined (1) the discount rate we use to discount the unpaid lease payments to present value, (2) lease term and (3) lease payments. ASC 842 requires a lessee to discount its unpaid lease payments using the interest rate implicit in the lease or, if that rate cannot be readily determined, its incremental borrowing rate. Because our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. Our incremental borrowing rate for a lease is the rate of interest we would have to pay on a collateralized basis to borrow an amount equal to the lease payments under similar terms. The lease term for all of our leases includes the noncancellable period of the lease. Lease payments included in the measurement of the lease asset or liability are comprised of our fixed payments. The ROU asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for lease payments made at or before the lease commencement date less any lease incentives received. For operating leases, the ROU asset is subsequently measured throughout the lease term at the carrying amount of the lease liability, plus (minus) any prepaid (accrued) lease payments, less the unamortized balance of lease incentives received. Lease expense for lease payments is recognized on a straight-line basis over the lease term. We monitor for events or changes in circumstances that require a reassessment of a lease. If a reassessment results in the remeasurement of a lease liability, a corresponding adjustment is made to the carrying amount of the corresponding ROU asset unless doing so would reduce the carrying amount of the ROU asset to an amount less than zero. In that case, the amount of the adjustment that would result in a negative ROU asset balance is recorded in profit or loss. We have elected not to recognize ROU assets and lease liabilities for all short-term leases that have a lease term of 12 months or less. We recognize the lease payments associated with our short-term leases as an expense on a straight-line basis over the lease term. Variable lease payments associated with these leases are recognized and presented in the same manner as for all our other leases. We adopted ASC 842 using a modified retrospective transition approach as of the effective date, as permitted by the amendments in ASU 2018-11. As a result, we were not required to adjust our comparative period financial information for effects of the standard or make the new required lease disclosures for periods before the date of adoption (i.e., January 1, 2019). We have elected to adopt the package of transition practical expedients and, therefore, have not reassessed (1) whether existing or expired contracts contain a lease, (2) lease classification for existing or expired leases or (3) the accounting for initial direct costs that were previously capitalized. We did not elect the practical expedient to use hindsight for leases existing at the adoption date. Further, we do not expect the amendments in ASU 2018-01: Land Easement Practical Expedient to have an effect on us because we do not enter into land easement arrangements. Cash, cash equivalents and marketable securities We consider all short‑term highly liquid investments with an original maturity at the date of purchase of three months or less to be cash equivalents. Cash and cash equivalents consist of account balances at banks and money market accounts, respectively. We invest our excess cash balances in marketable securities of highly rated financial institutions.  We seek to diversify our investments and limit the amount of investment concentrations for individual institutions, maturities and investment types. We classify marketable debt securities as available-for-sale and, accordingly, record such securities at fair value. We classify these securities as current assets as these investments are intended to be available to us for use in funding current operations. There were no marketable securities with a maturity of greater than one year as of March 31, 2020. Unrealized gains and losses on marketable debt securities are recorded as a separate component of accumulated other comprehensive income (loss) included in stockholders’ equity. Segment information Operating segments are identified as components of an enterprise for which separate discrete financial information is available for evaluation by the chief operating decision maker, or decision making group, in making decisions on how to allocate resources and assess performance. We view our operations and manage our business in one operating segment.  Net loss per share Basic net loss per share is calculated by dividing the net loss attributable to shareholders by the weighted average number of ordinary shares outstanding during the period. Diluted net loss per share is calculated by dividing the net loss attributable to shareholders by the weighted‑average number of ordinary shares outstanding for the period, including any dilutive effect from outstanding stock options or other equity-based awards. Shares used in the diluted net loss per share calculations exclude anti‑dilutive ordinary share equivalents, which currently consist of outstanding stock options, unvested restricted stock units (“RSUs”) and equity-classified warrants. The following potentially dilutive securities have been excluded from the computations of diluted weighted average shares outstanding as of March 31, 2020 and 2019, as they would be anti-dilutive: <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:71.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="middle" style="width:12.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="middle" style="width:00.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="middle" style="width:12.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:71.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="4" valign="bottom" style="width:25.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> March 31,  </td> </tr> <tr> <td valign="bottom" style="width:71.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2020 </td> <td colspan="2" valign="bottom" style="width:12.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2019 </td> </tr> <tr> <td valign="bottom" style="width:71.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Warrants </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="middle" style="width:12.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,803,253 </td> <td valign="middle" style="width:00.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="middle" style="width:12.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 6,833,253 </td> </tr> <tr> <td valign="bottom" style="width:71.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Stock options issued and outstanding </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">      </td> <td valign="bottom" style="width:00.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="middle" style="width:12.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 10,334,368 </td> <td valign="middle" style="width:00.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="middle" style="width:12.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 10,205,851 </td> </tr> <tr> <td valign="bottom" style="width:71.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Unvested RSUs </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="middle" style="width:12.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 925,800 </td> <td valign="middle" style="width:00.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="middle" style="width:12.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 758,850 </td> </tr> </table></div>   Recent accounting pronouncements – not yet adopted In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments. ASU 2016-13 requires an entity to measure and recognize expected credit losses for certain financial instruments, including trade receivables, as an allowance that reflects the entity's current estimate of credit losses expected to be incurred. For available-for-sale debt securities with unrealized losses, the standard requires allowances to be recorded through net income instead of directly reducing the amortized cost of the investment under the current other-than-temporary impairment model. The standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019 for SEC filers, excluding smaller reporting companies, who have until fiscal years beginning after December 15, 2022. We do not expect the adoption of this standard to have a significant impact on our financial statements or internal controls. <div /></div> </div>

372000

509000

649000

977000

1080000

980000

685000

228000

27000

68000

1000000

7500000

15000

1157000

1078000

14830000

166000

-18434000

-12698000

291000

270000

29000000

6583000

7552000

-260483000

-273181000

4343000

4333000

10000

6674000

6663000

11000

<div> <div> Accrued and other current liabilities consist of the following (in thousands): <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:74.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:74.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> March 31,  </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> December 31,  </td> <td valign="bottom" style="width:00.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:74.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:00.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:74.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2020 </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2019 </td> <td valign="bottom" style="width:00.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:74.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Consulting and professional fees </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 5,640 </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 4,335 </td> <td valign="bottom" style="width:00.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:74.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Supply agreement - current portion </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 4,391 </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2,773 </td> <td valign="bottom" style="width:00.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:74.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Accrued sales allowances </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2,229 </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2,990 </td> <td valign="bottom" style="width:00.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:74.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Employee compensation </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2,078 </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 4,452 </td> <td valign="bottom" style="width:00.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:74.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Accrued taxes </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,892 </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,892 </td> <td valign="bottom" style="width:00.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:74.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Severance </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 1,088 </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2,968 </td> <td valign="bottom" style="width:00.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:74.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Lease liability - current portion </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 384 </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 374 </td> <td valign="bottom" style="width:00.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:74.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Accrued royalties </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 302 </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 806 </td> <td valign="bottom" style="width:00.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:74.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Other </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 509 </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 372 </td> <td valign="bottom" style="width:00.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:74.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Total accrued liabilities </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 18,513 </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 20,962 </td> <td valign="bottom" style="width:00.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> </table></div>   <div /></div> </div>

<div> <div> We recognized stock‑based compensation expense for employees and directors for stock options and RSUs as follows (in thousands): <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:71.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:71.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:26.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Three Months Ended </td> </tr> <tr> <td valign="bottom" style="width:71.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="5" valign="bottom" style="width:26.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> March 31,  </td> </tr> <tr> <td valign="bottom" style="width:71.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2020 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:12.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2019 </td> </tr> <tr> <td valign="bottom" style="width:71.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Selling, general and administrative </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,270 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,811 </td> </tr> <tr> <td valign="bottom" style="width:71.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Research and development </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 481 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 512 </td> </tr> <tr> <td valign="bottom" style="width:71.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Total stock-based compensation </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,751 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2,323 </td> </tr> </table></div>   <div /></div> </div>

<div> <div> The following represents the balance of our intangible asset and goodwill as follows (in thousands): <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:30.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:19.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:21.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:17.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:30.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="8" valign="bottom" style="width:67.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> As of March 31, 2020 </td> <td valign="bottom" style="width:00.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:30.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:21.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Beginning of Period </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:23.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Amortization </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:19.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> End of Period </td> <td valign="bottom" style="width:00.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:30.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Keveyis </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:19.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 25,110 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:21.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (1,256) </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:17.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 23,855 </td> <td valign="bottom" style="width:00.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:30.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Goodwill </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:19.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 7,256 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:21.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:17.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 7,256 </td> <td valign="bottom" style="width:00.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:30.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Total </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:19.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 32,366 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:21.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (1,256) </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:17.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 31,111 </td> <td valign="bottom" style="width:00.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   <div /></div> </div>

<div> <div> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 79.62%;"> <tr> <td valign="bottom" style="width:78.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:18.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:78.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:18.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Number of </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:78.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:18.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Shares </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:78.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Outstanding—January 1, 2020 </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:18.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 791,350 </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:78.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Granted </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:18.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 212,650 </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:78.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Forfeited </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:18.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (17,200) </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:78.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Vested </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:18.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (61,000) </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:78.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Unvested—March 31, 2020 </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:18.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 925,800 </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   <div /></div> </div>

<div> <div> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:56.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:06.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:56.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="9" valign="bottom" style="width:41.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Options Outstanding </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:56.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:10.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:01.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:06.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Weighted- </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:56.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:10.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:06.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Average </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:56.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:10.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Weighted- </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Remaining </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:56.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:10.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Average </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Contractual </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:56.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:10.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Number of </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Exercise </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Term </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Aggregate </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:56.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:10.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Shares </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Price </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (Years) </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Intrinsic Value </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:56.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:10.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:06.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (in thousands) </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:56.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Outstanding—January 1, 2020 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 9,192,684 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 6.58 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 5.96 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 164 </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:56.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Granted </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2,393,000 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2.97 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:56.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Forfeited and cancelled </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (1,133,316) </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 10.66 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:56.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Exercised </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:56.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Outstanding—March 31, 2020 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 10,452,368 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 5.31 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2.01 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 104 </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:56.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Vested and exercisable—March 31, 2020 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 5,100,335 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 6.86 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 5.39 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  6 </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> </table></div>   <div /></div> </div>

<div> <div> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 81.16%;"> <tr> <td valign="bottom" style="width:61.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:16.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:61.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="3" valign="bottom" style="width:35.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Three Months Ended </td> <td valign="bottom" style="width:00.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:61.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="3" valign="bottom" style="width:35.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> March 31,  </td> <td valign="bottom" style="width:00.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:61.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">       </td> <td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2020 </td> <td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">       </td> <td valign="bottom" style="width:16.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2019 </td> <td valign="bottom" style="width:00.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:61.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Expected term (in years) </td> <td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 6.07 </td> <td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:16.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 6.09 </td> <td valign="bottom" style="width:00.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:61.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Risk-free interest rate </td> <td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 1.47%-1.48% </td> <td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:16.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2.47%-2.61% </td> <td valign="bottom" style="width:00.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:61.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Expected volatility </td> <td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 78.15%-78.21% </td> <td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:16.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 80.00%-80.85% </td> <td valign="bottom" style="width:00.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:61.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Dividend rate </td> <td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> —% </td> <td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:16.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> —% </td> <td valign="bottom" style="width:00.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> </table></div>   <div /></div> </div>

<div> <div> <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:32.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:05.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:32.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:05.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Warrants </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:32.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:05.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Outstanding </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:32.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Exercise </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Expiration </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Warrants </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Warrants </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> March 31,  </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:32.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Classification </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Price </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Date </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Issued </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Exercised </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2020 </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:32.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Warrants in connection with private equity placement </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">      </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Liability </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">      </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2.50 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">      </td> <td valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 6/28/2022 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">      </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 7,000,000 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (1,970,000) </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 5,030,000 </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:32.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Warrants in connection with Horizon and Oxford loan agreement </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Equity </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2.45 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 12/28/2026 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 428,571 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (267,857) </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 160,714 </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:32.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Warrants in connection with CRG loan agreement </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Equity </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 7.37 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 7/14/2024 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 394,289 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 394,289 </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:32.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Warrants in connection with CRG loan amendment in January 2018 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Equity </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 10.00 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 1/16/2025 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 1,248,250 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 1,248,250 </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:32.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:05.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 9,071,110 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 6,833,253 </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   <div /></div> </div>

12100000

10403000

2323000

1751000

P1Y

P2Y

P1Y

17200

212650

791350

925800

61000

P6Y1M2D

P6Y26D

0.8085

0.7821

0.8000

0.7815

0.0261

0.0148

0.0247

0.0147

561158

1374528

271029

6000

5100335

6.86

P5Y4M21D

1133316

2393000

164000

104000

9192684

10452368

6.58

5.31

P5Y11M16D

P2Y4D

10.66

2.97

7.00

40000

54122074

40000

54167948

54205852

54247501

112955000

44000

323402000

541000

-211032000

96983000

44000

325863000

542000

-229466000

72191000

44000

3000

332085000

542000

-260483000

61179000

44000

6000

333768000

542000

-273181000

6146

41649

-27000

1000

-68000

1000

166000

165000

1000

false

1892000

4127000

3547000

54155034

54444681

54155034

54231024

EX-101.SCH 6 sbbp-20200331.xsd EX-101.SCH 00100 - Statement - Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00200 - Statement - Consolidated Statements of Operations and Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 00400 - Statement - Consolidated Statements of Cash Flow link:presentationLink link:calculationLink link:definitionLink 40401 - Disclosure - Fair value measurement - Assets and liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 40501 - Disclosure - Marketable securities (Details) link:presentationLink link:calculationLink link:definitionLink 40601 - Disclosure - Intangible asset and goodwill - Components (Details) link:presentationLink link:calculationLink link:definitionLink 40701 - Disclosure - Accrued and other current liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 00090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00105 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00300 - Statement - Consolidated Statement of Stockholders’ Equity link:presentationLink link:calculationLink link:definitionLink 10101 - Disclosure - Organization link:presentationLink link:calculationLink link:definitionLink 10201 - Disclosure - Summary of significant accounting policies and basis of presentation link:presentationLink link:calculationLink link:definitionLink 10301 - Disclosure - Revenue recognition link:presentationLink link:calculationLink link:definitionLink 10401 - Disclosure - Fair value measurement link:presentationLink link:calculationLink link:definitionLink 10601 - Disclosure - Intangible assets and goodwill link:presentationLink link:calculationLink link:definitionLink 10701 - Disclosure - Accrued and other current liabilities link:presentationLink link:calculationLink link:definitionLink 10801 - Disclosure - Commitments and contingencies link:presentationLink link:calculationLink link:definitionLink 10901 - Disclosure - Income taxes link:presentationLink link:calculationLink link:definitionLink 11001 - Disclosure - Warrants link:presentationLink link:calculationLink link:definitionLink 11101 - Disclosure - Stock-based compensation link:presentationLink link:calculationLink link:definitionLink 20202 - Disclosure - Summary of significant accounting policies and basis of presentation (Policies) link:presentationLink link:calculationLink link:definitionLink 30203 - Disclosure - Summary of significant accounting policies and basis of presentation (Tables) link:presentationLink link:calculationLink link:definitionLink 30403 - Disclosure - Fair value measurement (Tables) link:presentationLink link:calculationLink link:definitionLink 30603 - Disclosure - Intangible assets and goodwill (Tables) link:presentationLink link:calculationLink link:definitionLink 30703 - Disclosure - Accrued and other current liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 31003 - Disclosure - Warrants (Tables) link:presentationLink link:calculationLink link:definitionLink 31103 - Disclosure - Stock-based compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 40101 - Disclosure - Organization - Products (Details) link:presentationLink link:calculationLink link:definitionLink 40102 - Disclosure - Organization - Sale of subsidiary (Details) link:presentationLink link:calculationLink link:definitionLink 40103 - Disclosure - Organization - Liquidity (Details) link:presentationLink link:calculationLink link:definitionLink 40201 - Disclosure - Summary of significant accounting policies and basis of presentation - Leases (Details) link:presentationLink link:calculationLink link:definitionLink 40202 - Disclosure - Summary of significant accounting policies and basis of presentation - Marketable securities and Segment information (Details) link:presentationLink link:calculationLink link:definitionLink 40203 - Disclosure - Summary of significant accounting policies and basis of presentation - Anti-dilutive securities (Details) link:presentationLink link:calculationLink link:definitionLink 40301 - Disclosure - Revenue recognition - Product sales (Details) link:presentationLink link:calculationLink link:definitionLink 40302 - Disclosure - Revenue recognition - Reserves (Details) link:presentationLink link:calculationLink link:definitionLink 40402 - Disclosure - Fair value measurement - Level 3 (Details) link:presentationLink link:calculationLink link:definitionLink 40602 - Disclosure - Intangible asset and goodwill - Asset purchase (Details) link:presentationLink link:calculationLink link:definitionLink 40801 - Disclosure - Commitments and contingencies - Commitments to Taro (Details) link:presentationLink link:calculationLink link:definitionLink 40901 - Disclosure - Income taxes (Details) link:presentationLink link:calculationLink link:definitionLink 41001 - Disclosure - Warrants (Details) link:presentationLink link:calculationLink link:definitionLink 41101 - Disclosure - Stock-based compensation - General (Details) link:presentationLink link:calculationLink link:definitionLink 41102 - Disclosure - Stock-based compensation - Stock options activity (Details) link:presentationLink link:calculationLink link:definitionLink 41103 - Disclosure - Stock-based compensation - Stock-based compensation expense (Details) link:presentationLink link:calculationLink link:definitionLink 41104 - Disclosure - Stock-based compensation - Fair value assumptions (Details) link:presentationLink link:calculationLink link:definitionLink 41105 - Disclosure - Stock-based compensation - Restricted stock units (Details) link:presentationLink link:calculationLink link:definitionLink 10501 - Disclosure - Marketable securities link:presentationLink link:calculationLink link:definitionLink 30503 - Disclosure - Marketable securities (Tables) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 sbbp-20200331_cal.xml EX-101.CAL EX-101.DEF 8 sbbp-20200331_def.xml EX-101.DEF EX-101.LAB 9 sbbp-20200331_lab.xml EX-101.LAB No definition available. Document and Entity Information [Abstract] Statement [Table] Statement [Line Items] Document Type Document Period End Date Entity Registrant Name Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Entity Ex Transition Period Entity Shell Company Entity Common Stock, Shares Outstanding Entity Central Index Key Current Fiscal Year End Date Document Fiscal Year Focus Document Fiscal Period Focus Amendment Flag Consolidated Balance Sheets Assets [Abstract] ASSETS Assets, Current [Abstract] Current assets: Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents Debt Securities, Available-for-sale, Current Marketable securities Fair Value Accounts Receivable, Net, Current Accounts receivable Inventory, Net Inventory Prepaid Expense and Other Assets, Current Prepaid expenses and other current assets Assets, Current Total current assets Property, Plant and Equipment, Net Property and equipment, net Operating Lease, Right-of-Use Asset Right of use asset, net Intangible Assets, Net (Excluding Goodwill) Intangible asset, net Goodwill Goodwill, End of Period Goodwill, Beginning of Period Goodwill Other Assets, Noncurrent Other assets Assets Total assets Liabilities and Equity [Abstract] LIABILITIES AND STOCKHOLDERS’ EQUITY Accrued Liabilities, Current [Abstract] Current liabilities: Accounts Payable Accounts payable Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Also includes amount of liabilities classified as other, due within one year or the normal operating cycle, if longer. Accrued Liabilities and Other Liabilities, Current Accrued and other current liabilities Liabilities, Current Total current liabilities Warrants and Rights Outstanding Warrant liability Warrant liability Carrying value as of the balance sheet date of obligations incurred through that date and due beyond one year (or beyond one operating cycle if longer) in connection with supply agreement. Accrued Liabilities, Supply Agreement, Noncurrent Supply agreement liability, noncurrent Other Liabilities, Noncurrent Other long-term liabilities Liabilities Total liabilities Commitments and Contingencies. Commitments and contingencies (Note 8) Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract] Stockholders’ equity: Aggregate par or state value of deferred shares issued in order to satisfy legislative requirement to maintain a minimum level of issued share capital denominated in euro. Deferred Shares, Value Deferred shares, $1.098 par value, 40,000 shares authorized, issued and outstanding at March 31, 2020 and December 31, 2019 Common Stock, Value, Issued Ordinary shares, $0.01 par value, 600,000,000 shares authorized at March 31, 2020 and December 31, 2019; 54,247,501 and 54,205,852 shares issued and outstanding at March 31, 2020 and December 31, 2019 Additional Paid in Capital, Common Stock Additional paid-in capital Retained Earnings (Accumulated Deficit) Accumulated deficit Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated other comprehensive income Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Balance at end of period Balance at beginning of period Total stockholders’ equity Liabilities and Equity Total liabilities and stockholders’ equity Face amount or stated value per share of deferred shares. Deferred Shares, Par Or Stated Value Per Share Deferred shares, par value (in dollars per share) The maximum number of deferred shares permitted to be issued by an entity's charter and bylaws. Deferred Shares , Shares Authorized Deferred shares, shares authorized Total number of deferred shares of an entity that have been sold or granted to shareholders (includes related deferred shares that were issued, repurchased, and remain in the treasury). Deferred Shares , Shares Issued Deferred shares, shares issued Number of deferred stock of stock outstanding. Deferred Shares, Shares Outstanding Deferred shares, shares outstanding Common Stock, Par or Stated Value Per Share Ordinary shares, par value (in dollars per share) Common Stock, Shares Authorized Ordinary shares, shares authorized Common Stock, Shares, Issued Ordinary shares, shares issued Common Stock, Shares, Outstanding Ordinary shares, shares outstanding Consolidated Statements of Operations and Comprehensive Loss Revenues [Abstract] Revenues: Revenue, Net Total revenues Operating Expenses [Abstract] Cost and expenses: Cost of Goods and Service, Excluding Depreciation, Depletion, and Amortization Cost of sales (excluding amortization of intangible asset) Selling, General and Administrative Expense Selling, general and administrative Research and Development Expense Research and development Amortization of Intangible Assets Finite-lived intangible assets, Amortization Amortization of intangible asset Amortization of intangible asset Costs and Expenses Total cost and expenses Operating Income (Loss) Operating loss Nonoperating Income (Expense) [Abstract] Other income (expenses), net: Fair Value Adjustment of Warrants Unrealized gain (loss) on fair value of warrants Change in fair value of warrant liability The amount of income from field service reimbursement. Nonoperating Income, Income From Field Service Reimbursement Income from field services agreement The amount of expense from field service reimbursement. Nonoperating Expense, Expense From Field Service reimbursement Expense from field services agreement Other Nonoperating Income (Expense) Other income, net Nonoperating Income (Expense) Total other income (expenses), net Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Loss before income taxes Income Tax Expense (Benefit) Income tax expense Income tax expense Net Income (Loss) Attributable to Parent Net loss Net loss Debt Securities, Available-for-sale, Unrealized Gain Unrealized gain on marketable securities Comprehensive Income (Loss), Net of Tax, Attributable to Parent Comprehensive loss No definition available. Net Income (Loss) Available to Common Stockholders, Basic and Diluted [Abstract] Net loss attributable to ordinary shareholders: Net Income (Loss) Available to Common Stockholders, Basic Basic Net Income (Loss) Available to Common Stockholders, Diluted Diluted Earnings Per Share, Basic and Diluted [Abstract] Net loss per share attributable to ordinary shareholders: Earnings Per Share, Basic Basic (in dollars per share) Earnings Per Share, Diluted Diluted (in dollars per share) Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract] Weighted-average shares used in computing net loss per share attributable to ordinary shareholders: Weighted Average Number of Shares Outstanding, Basic Basic (in shares) Weighted Average Number of Shares Outstanding, Diluted Diluted (in shares) Consolidated Statement of Stockholders’ Equity Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity Shares, Outstanding Balance (in shares) Balance (in shares) Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition Stock-based compensation Number of shares issued during the period for sale of subsidiary. Stock Issued During Period, Shares, Sale of Subsidiary Issuance of shares to Novo (in shares) Stock Issued, Value, Stock Options Exercised, Net of Tax Benefit (Expense) Exercise of stock options Number of stock issued as a result of the exercise of stock options, in net of tax settlement. Stock Issued, Shares, Stock Options Exercised, Net of Tax Exercise of stock options (in shares) Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures Ordinary shares issued, net of shares withheld for employee taxes Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures Ordinary shares issued, net of shares withheld for employee taxes (in shares) Consolidated Statements of Cash Flow Net Cash Provided by (Used in) Operating Activities [Abstract] Cash flows from operating activities: Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net loss Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Share-based Compensation Stock-based compensation Amount of accretion of purchase discount on nonoperating securities. Accretion Of Discounts On Marketable Securities Accretion of discounts on marketable securities Depreciation Increase (Decrease) in Operating Capital [Abstract] Changes in operating assets and liabilities: Increase (Decrease) in Accounts Receivable Accounts receivable Increase (Decrease) in Inventories Inventory Increase (Decrease) in Prepaid Expense and Other Assets Prepaid expenses and other current assets Increase (Decrease) in Other Noncurrent Assets Other assets Increase (Decrease) in Accounts Payable Accounts payable Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities Accrued and other liabilities Net Cash Provided by (Used in) Operating Activities Net cash used in operating activities Net Cash Provided by (Used in) Investing Activities [Abstract] Cash flows from investing activities: Payments to Acquire Property, Plant, and Equipment Purchases of property and equipment Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale Maturities of marketable securities Net Cash Provided by (Used in) Investing Activities Net cash provided by (used in) investing activities Net Cash Provided by (Used in) Financing Activities [Abstract] Cash flows from financing activities: Proceeds from Stock Options Exercised Proceeds from exercise of stock options Payments Related to Tax Withholding for Share-based Compensation Payments related to tax withholding for net-share settled equity awards Net Cash Provided by (Used in) Financing Activities Net cash (used in) provided by financing activities Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Net decrease in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Cash and cash equivalents—end of period Cash and cash equivalents—beginning of period Noncash Investing and Financing Items [Abstract] Supplemental non-cash financing activities: The amount of non cash increase (decrease) in unrealized gain on available for sale debt securities. Noncash Increase (Decrease) In Unrealized Gain On Available For Sale Debt Securities Changes in unrealized gain on marketable securities Organization Nature of Operations [Text Block] Organization Summary of significant accounting policies and basis of presentation Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block] Summary of significant accounting policies and basis of presentation Revenue recognition Disclosure pertaining to revenue. Revenues Disclosure [Text Block] Revenue recognition Fair value measurement Fair Value Disclosures [Text Block] Fair value measurement Marketable securities Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] Marketable securities Intangible asset and goodwill Goodwill and Intangible Assets Disclosure [Text Block] Intangible assets and goodwill Accrued and other current liabilities Accounts Payable and Accrued Liabilities Disclosure [Text Block] Accrued and other current liabilities Commitments and contingencies Commitments and Contingencies Disclosure [Text Block] Commitments and contingencies Income taxes Income Tax Disclosure [Text Block] Income taxes Warrants The entire disclosure of warrants issued and outstanding. Warrants Note Disclosure [Text Block] Warrants Stock-based compensation Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Stock based compensation Basis of Accounting, Policy [Policy Text Block] Basis of presentation Disclosure of accounting policy for lessee operating leases. Lessee, Operating Leases Policy [Policy Text Block] Leases Cash and Cash Equivalents, Policy [Policy Text Block] Cash and cash equivalents Marketable Securities, Policy [Policy Text Block] Marketable securities Segment Reporting, Policy [Policy Text Block] Segment information Earnings Per Share, Policy [Policy Text Block] Net income (loss) per share New Accounting Pronouncements, Policy [Policy Text Block] Recently issued accounting pronouncements Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Schedule of potentially dilutive securities excluded from computations of diluted weighted average shares outstanding Fair Value Measurements, Recurring and Nonrecurring [Table Text Block] Schedule of fair value of financial assets by level Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Schedule of reconciliation of level 3 Warrant liability Debt Securities, Available-for-sale [Table Text Block] Schedule of amortized cost, gross unrealized holding gains, gross unrealized holding losses and fair value of available-for-sale debt securities by type of security Schedule of Intangible Assets and Goodwill [Table Text Block] Schedule of gross carrying amount of in process research and development and goodwill Schedule of Accrued Liabilities [Table Text Block] Schedule of accrued and other current liabilities Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] Schedule of warrants Share-based Compensation, Stock Options, Activity [Table Text Block] Schedule of summary of outstanding stock options activity Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block] Schedule of stock-based compensation Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Schedule of assumptions for estimating fair value of stock option awards Schedule of Share-based Compensation, Restricted Stock Units Award Activity [Table Text Block] Schedule of summary of unvested RSUs Number of clinical-stage product candidates. Products, Clinical Stage, Number Number of clinical-stage product candidates Disposal Groups, Including Discontinued Operations [Table] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Sale of subsidiary Disposal Group, Including Discontinued Operation, Consideration Consideration for sale of subsidiary Number of entity's employees funded by counterparty to provide services to counterparty under the terms of the agreement. Number of Employees, Counterparty Number of employees funded by counterparty Term of agreement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Term of Agreement Term of agreement Shares Issued, Price Per Share Price per share (in dollars per share) The amount of cash inflow from termination of agreement. Proceeds From Termination Of Agreement Termination payment Schedule of Long-term Debt Instruments [Table] Debt Instrument [Line Items] No definition available. Liquidity [Abstract] Liquidity Cash, Cash Equivalents, and Short-term Investments Cash, cash equivalents and marketable securities Substantial Doubt about Going Concern, within One Year Substantial doubt about going concern, within one year New Accounting Pronouncements or Change in Accounting Principle [Table] New Accounting Pronouncements or Change in Accounting Principle [Line Items] Recently issued accounting pronouncements Operating Lease, Liability, Statement of Financial Position [Extensible List] Operating Lease, Liability, Statement of Financial Position Change in Accounting Principle, Accounting Standards Update, Adopted [true false] Change in Accounting Principle, Accounting Standards Update, Adopted Change in Accounting Principle, Accounting Standards Update, Transition Option Elected [Fixed List] Change in Accounting Principle, Accounting Standards Update, Transition Option Elected New Accounting Pronouncement or Change in Accounting Principle, Prior Period Not Restated [true false] New Accounting Pronouncement or Change in Accounting Principle, Prior Period Not Restated Lease, Practical Expedients, Package [true false] Lease, Practical Expedients, Package Lease, Practical Expedient, Use of Hindsight [true false] Lease, Practical Expedient, Use of Hindsight Segment and other information Segment information Debt Securities, Available-for-sale, Noncurrent Marketable securities, noncurrent Number of Operating Segments Number of operating segments Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive securities Earnings Per Share [Abstract] Net loss per share Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Anti-dilutive shares of common stock (in shares) EX-101.PRE 10 sbbp-20200331_pre.xml EX-101.PRE XML 11 R15.htm IDEA: XBRL DOCUMENT

Income taxes	3 Months Ended
Income taxes	Mar. 31, 2020
Income taxes
Income taxes	9. Income taxes Deferred tax assets and liabilities are recognized for the future tax consequences of differences between the carrying amounts and tax bases of assets and liabilities and operating loss carryforwards and other attributes using enacted rates expected to be in effect when those differences reverse. Valuation allowances are provided against deferred tax assets that are not more likely than not to be realized. We assess our ability to realize deferred tax assets. Changes in future earnings projections, among other factors, may cause us to adjust our valuation allowance on deferred tax assets. Any such adjustments would impact our income tax expense in the period in which it is determined that these factors have changed. We did not incur income any tax expense for the three months ended March 31, 2020.

XML 12 R11.htm IDEA: XBRL DOCUMENT

Marketable securities

3 Months Ended

Mar. 31, 2020

Marketable securities

Marketable securities

5. Marketable securities

Marketable securities consist of the following:


	As of March 31, 2020
	Amortized Cost		Net Unrealized Gain		Fair Value
Commercial paper	$	3,293	$	—	$	3,293
U.S. treasury securities		2,994		6		3,000
Total marketable securities	$	6,287	$	6	$	6,293

XML 13 R19.htm IDEA: XBRL DOCUMENT

Summary of significant accounting policies and basis of presentation (Tables)

3 Months Ended

Mar. 31, 2020

Summary of significant accounting policies and basis of presentation

Schedule of potentially dilutive securities excluded from computations of diluted weighted average shares outstanding


	March 31,
	2020		2019
Warrants		1,803,253		6,833,253
Stock options issued and outstanding		10,334,368		10,205,851
Unvested RSUs		925,800		758,850

XML 14 R32.htm IDEA: XBRL DOCUMENT

Revenue recognition - Product sales (Details)	Mar. 31, 2020 customer
Revenue recognition
Number of specialty provider	1

XML 15 R36.htm IDEA: XBRL DOCUMENT

Marketable securities (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Marketable securities
Amortized Cost	$ 6,287
Net Unrealized Gains	6
Fair Value	6,293	$ 21,072
Commercial paper
Marketable securities
Amortized Cost	3,293
Fair Value	3,293
U.S. treasury securities
Marketable securities
Amortized Cost	2,994
Net Unrealized Gains	6
Fair Value	$ 3,000

XML 16 R3.htm IDEA: XBRL DOCUMENT

Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2020	Dec. 31, 2019
Consolidated Balance Sheets
Deferred shares, par value (in dollars per share)	$ 1.098	$ 1.098
Deferred shares, shares authorized	40,000	40,000
Deferred shares, shares issued	40,000	40,000
Deferred shares, shares outstanding	40,000	40,000
Ordinary shares, par value (in dollars per share)	$ 0.01	$ 0.01
Ordinary shares, shares authorized	600,000,000	600,000,000
Ordinary shares, shares issued	54,247,501	54,205,852
Ordinary shares, shares outstanding	54,247,501	54,205,852

XML 17 R7.htm IDEA: XBRL DOCUMENT

Organization	3 Months Ended
Organization	Mar. 31, 2020
Organization
Organization	1. Organization We are a global, commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs. Our first commercial product is Keveyis (dichlorphenamide), the first and only treatment approved by the U.S. Food and Drug Administration (the “FDA”) for hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (“PPP”), a group of rare hereditary disorders that cause episodes of muscle weakness or paralysis. We have two clinical-stage product candidates for rare endocrine diseases, Recorlev and veldoreotide. Recorlev (levoketoconazole) is a cortisol synthesis inhibitor currently being studied for the treatment of endogenous Cushing's syndrome. Veldoreotide is a next-generation somatostatin analog being investigated for potential applications in conditions amenable to somatostatin receptor activation, such as acromegaly. Both levoketoconazole and veldoreotide have received orphan designation from the FDA and the European Medicines Agency (“EMA”). In January 2018, Strongbridge Ireland Limited, one of our wholly-owned subsidiaries, acquired the U.S. and Canadian rights to Macrilen (macimorelin), the first and only oral drug approved by the FDA for the diagnosis of patients with adult growth hormone deficiency. We launched Macrilen in the United States in July 2018. In December 2018, we sold Strongbridge Ireland Limited to Novo Nordisk Healthcare AG (“Novo”) for $145 million plus the right to receive tiered royalties on net sales of Macrilen through 2027. In addition, Strongbridge U.S. Inc., another of our wholly-owned subsidiaries, entered into an agreement with Novo Nordisk Inc. (“NNI”), a subsidiary of Novo, pursuant to which NNI funded the costs of 23 of our field-based employees to provide full-time ongoing services to NNI, including the promotion of Macrilen in the United States, for a period of three years. Novo also purchased 5.2 million of our ordinary shares at a purchase price of $7.00 per share. In December 2019, we reached an agreement with Novo to terminate the services agreement. We received a $6 million payment in connection with such termination and we no longer provide services to Novo. Liquidity We believe that our cash, cash equivalents and marketable securities of $62.8 million at March 31, 2020 will be sufficient to allow us to fund planned operations for at least 12 months beyond the issuance date of these unaudited consolidated financial statements. We may never achieve profitability, and unless and until we do, we will continue to need to raise additional capital. We plan to continue to fund our operations and capital funding needs through equity or debt financing along with revenues from Keveyis. There can be no assurances, however, that additional funding will be available on terms acceptable to us.

XML 18 R27.htm IDEA: XBRL DOCUMENT

Organization - Sale of subsidiary (Details) $ / shares in Units, shares in Millions, $ in Millions	1 Months Ended
	Dec. 31, 2019 USD ($)	Dec. 31, 2018 USD ($) employee $ / shares shares
Disposal Group, Disposed of by Sale, Not Discontinued Operations \| Strongbridge Ireland Ltd.
Sale of subsidiary
Consideration for sale of subsidiary		$ 145
Novo
Sale of subsidiary
Termination payment	$ 6
Novo \| Ordinary Shares
Sale of subsidiary
Issuance of shares to Novo (in shares) \| shares		5.2
Price per share (in dollars per share) \| $ / shares		$ 7.00
NNI \| Services Agreement
Sale of subsidiary
Number of employees funded by counterparty \| employee		23
Term of agreement		3 years

XML 19 R23.htm IDEA: XBRL DOCUMENT

Accrued and other current liabilities (Tables)

3 Months Ended

Mar. 31, 2020

Accrued and other current liabilities

Schedule of accrued and other current liabilities

Accrued and other current liabilities consist of the following (in thousands):


	March 31,		December 31,

	2020		2019
Consulting and professional fees	$	5,640	$	4,335
Supply agreement - current portion		4,391		2,773
Accrued sales allowances		2,229		2,990
Employee compensation		2,078		4,452
Accrued taxes		1,892		1,892
Severance		1,088		2,968
Lease liability - current portion		384		374
Accrued royalties		302		806
Other		509		372
Total accrued liabilities	$	18,513	$	20,962

XML 20 R42.htm IDEA: XBRL DOCUMENT

Warrants (Details)	3 Months Ended
Warrants (Details)	Mar. 31, 2020 $ / shares shares
Warrants
Warrants Issued (in shares)	9,071,110
Warrants Outstanding (in shares)	6,833,253
Warrants in connection with private equity placement
Warrants
Exercise Price (in dollars per share) \| $ / shares	$ 2.50
Warrants Issued (in shares)	7,000,000
Warrants Exercised (in shares)	(1,970,000)
Warrants Outstanding (in shares)	5,030,000
Warrants in connection with Horizon and Oxford loan agreement
Warrants
Exercise Price (in dollars per share) \| $ / shares	$ 2.45
Warrants Issued (in shares)	428,571
Warrants Exercised (in shares)	(267,857)
Warrants Outstanding (in shares)	160,714
Warrants in connection with CRG loan agreement
Warrants
Exercise Price (in dollars per share) \| $ / shares	$ 7.37
Warrants Issued (in shares)	394,289
Warrants Outstanding (in shares)	394,289
Warrants in connection with CRG loan amendment in January 2018
Warrants
Exercise Price (in dollars per share) \| $ / shares	$ 10.00
Warrants Issued (in shares)	1,248,250
Warrants Outstanding (in shares)	1,248,250

XML 21 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 22 R46.htm IDEA: XBRL DOCUMENT

Stock-based compensation - Fair value assumptions (Details)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Fair value assumptions
Expected term (in years)	6 years 26 days	6 years 1 month 2 days
Minimum Risk-free interest rate (as a percent)	1.47%	2.47%
Maximum Risk-free interest rate (as a percent)	1.48%	2.61%
Minimum Expected volatility (as a percent)	78.15%	80.00%
Maximum Expected volatility (as a percent)	78.21%	80.85%

XML 23 R26.htm IDEA: XBRL DOCUMENT

Organization - Products (Details)	Mar. 31, 2020 product
Organization
Number of clinical-stage product candidates	2

XML 24 R22.htm IDEA: XBRL DOCUMENT

Intangible assets and goodwill (Tables)

3 Months Ended

Mar. 31, 2020

Intangible asset and goodwill

Schedule of gross carrying amount of in process research and development and goodwill

The following represents the balance of our intangible asset and goodwill as follows (in thousands):


	As of March 31, 2020
	Beginning of Period		Amortization		End of Period
Keveyis	$	25,110	$	(1,256)	$	23,855
Goodwill		7,256		—		7,256
Total	$	32,366	$	(1,256)	$	31,111

XML 25 R2.htm IDEA: XBRL DOCUMENT

Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 56,554	$ 57,032
Marketable securities	6,293	21,072
Accounts receivable	2,690	2,289
Inventory	1,343	1,993
Prepaid expenses and other current assets	1,078	1,157
Total current assets	67,958	83,543
Property and equipment, net	270	291
Right of use asset, net	744	789
Intangible asset, net	23,855	25,110
Goodwill	7,256	7,256
Other assets	977	649
Total assets	101,060	117,638
Current liabilities:
Accounts payable	5,285	3,331
Accrued and other current liabilities	18,513	20,962
Total current liabilities	23,798	24,293
Warrant liability	3,547	4,127
Supply agreement liability, noncurrent	11,556	15,947
Other long-term liabilities	980	1,080
Total liabilities	39,881	45,447
Commitments and contingencies (Note 8)
Stockholders’ equity:
Deferred shares, $1.098 par value, 40,000 shares authorized, issued and outstanding at March 31, 2020 and December 31, 2019	44	44
Ordinary shares, $0.01 par value, 600,000,000 shares authorized at March 31, 2020 and December 31, 2019; 54,247,501 and 54,205,852 shares issued and outstanding at March 31, 2020 and December 31, 2019	542	542
Additional paid-in capital	333,768	332,085
Accumulated deficit	(273,181)	(260,483)
Accumulated other comprehensive income	6	3
Total stockholders’ equity	61,179	72,191
Total liabilities and stockholders’ equity	$ 101,060	$ 117,638

XML 26 R6.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Cash Flow - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Cash flows from operating activities:
Net loss	$ (12,698)	$ (18,434)
Adjustments to reconcile net loss to net cash used in operating activities:
Change in fair value of warrant liability	(580)	1,820
Stock-based compensation	1,751	2,323
Amortization of intangible asset	1,256	1,256
Accretion of discounts on marketable securities	(48)
Depreciation	21	18
Changes in operating assets and liabilities:
Accounts receivable	(401)	(2,290)
Inventory	101	(649)
Prepaid expenses and other current assets	79	1,510
Other assets	266	(1,210)
Accounts payable	1,954	539
Accrued and other liabilities	(6,941)	(3,191)
Net cash used in operating activities	(15,240)	(18,308)
Cash flows from investing activities:
Purchases of property and equipment		(15)
Maturities of marketable securities	14,830
Net cash provided by (used in) investing activities	14,830	(15)
Cash flows from financing activities:
Proceeds from exercise of stock options		166
Payments related to tax withholding for net-share settled equity awards	(68)	(27)
Net cash (used in) provided by financing activities	(68)	139
Net decrease in cash and cash equivalents	(478)	(18,184)
Cash and cash equivalents—beginning of period	57,032	122,490
Cash and cash equivalents—end of period	56,554	$ 104,306
Supplemental non-cash financing activities:
Changes in unrealized gain on marketable securities	$ 3

XML 27 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 28 R43.htm IDEA: XBRL DOCUMENT

Stock-based compensation - General (Details)	Mar. 31, 2020 shares
Inducement Plan
Stock-based compensation
Number of shares available for issuance	1,374,528
2015 Plan
Stock-based compensation
Number of shares available for issuance	561,158
Non-Employee Director Plan
Stock-based compensation
Number of shares available for issuance	271,029

XML 29 R47.htm IDEA: XBRL DOCUMENT

Stock-based compensation - Restricted stock units (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Stock-based compensation
Stock-based compensation	$ 1,751	$ 2,323
RSUs
Stock-based compensation
Number of shares issued for each stock award vested	1
Stock-based compensation	$ 500	$ 500
Total unrecognized compensation expense	$ 1,600
Estimated weighted average period over which expense is expected to be recognized	1 year 2 months 16 days
Summary of unvested RSUs
Unvested - Beginning of period (in shares)	791,350
Granted (in shares)	212,650
Forfeited (in shares)	(17,200)
Vested (in shares)	(61,000)
Unvested - End of period (in shares)	925,800
RSUs \| Employee
Stock-based compensation
Vesting period	2 years
RSUs \| Director
Stock-based compensation
Vesting period	1 year
Service period	1 year

XML 30 R18.htm IDEA: XBRL DOCUMENT

Summary of significant accounting policies and basis of presentation (Policies)

3 Months Ended

Mar. 31, 2020

Summary of significant accounting policies and basis of presentation

Basis of presentation

The preparation of the unaudited consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect reported amounts and disclosures in the consolidated financial statements. Actual results could differ from those estimates. Results for the three months ended March 31, 2020 are not necessarily indicative of the results that may be expected for the year ending December 31, 2020.

Leases

Key estimates and judgments include how we determined (1) the discount rate we use to discount the unpaid lease payments to present value, (2) lease term and (3) lease payments.

The lease term for all of our leases includes the noncancellable period of the lease. Lease payments included in the measurement of the lease asset or liability are comprised of our fixed payments.

Cash and cash equivalents

Cash, cash equivalents and marketable securities

Marketable securities

Unrealized gains and losses on marketable debt securities are recorded as a separate component of accumulated other comprehensive income (loss) included in stockholders’ equity.

Segment information

Net income (loss) per share

Net loss per share

The following potentially dilutive securities have been excluded from the computations of diluted weighted average shares outstanding as of March 31, 2020 and 2019, as they would be anti-dilutive:


	March 31,
	2020		2019
Warrants		1,803,253		6,833,253
Stock options issued and outstanding		10,334,368		10,205,851
Unvested RSUs		925,800		758,850

Recently issued accounting pronouncements

Recent accounting pronouncements – not yet adopted

XML 31 R14.htm IDEA: XBRL DOCUMENT

Commitments and contingencies	3 Months Ended
Commitments and contingencies	Mar. 31, 2020
Commitments and contingencies
Commitments and contingencies	8. Commitments and contingencies (a) Commitments to Taro Pharmaceuticals Industries Ltd. In December 2016, we acquired the U.S. marketing rights to Keveyis (dichlorphenamide) from Taro. Under the terms of an Asset Purchase Agreement, we paid Taro an upfront payment in two installments of $1 million in December 2016 and $7.5 million in March 2017, and will pay an aggregate of $7.5 million in potential milestones upon the achievement of certain product sales targets. Taro has agreed to continue to manufacture Keveyis for us under an exclusive supply agreement through the orphan exclusivity period. We are obligated to purchase certain annual minimum amounts of product totaling approximately $29 million over a six-year period. As of March 31, 2020, our remaining obligation was $19.0 million. Our Supply Agreement with Taro may extend beyond the orphan exclusivity period unless terminated by either party pursuant to the terms of the agreement. If terminated by Taro at the conclusion of the orphan exclusivity period, we have the right to manufacture the product on our own or have the product manufactured by a third party on our behalf. We are also required to reimburse Taro for their royalty obligation resulting from their sale of Keveyis to us. (b) Indemnifications In the ordinary course of business and in connection with the sale of assets and businesses and other transactions, we often indemnify our counterparties against certain liabilities that may arise in connection with the transaction or that are related to events and activities prior to or following a transaction, such as breaches of contracts, unfavorable tax consequences and employee liabilities. If the indemnified party were to make a successful claim pursuant to the terms of the indemnification, we may be required to reimburse the loss and such amount could be material to our financial statements. Where appropriate, the obligation for such indemnifications is recorded as a liability. Because the amount of these types of indemnifications generally is not specifically stated, the overall maximum amount of the obligation under such indemnifications cannot be reasonably estimated. However, we believe that the likelihood of a material liability being triggered under these indemnification obligations is not probable at this time.

XML 32 R10.htm IDEA: XBRL DOCUMENT

Fair value measurement

3 Months Ended

Mar. 31, 2020

Fair value measurement

Fair value measurement

4. Fair value measurement

The guidance requires fair value measurements to maximize the use of “observable inputs.” The three-level hierarchy of inputs to measure fair value are as follows:

We did not have any transfers between the different levels.

The following table presents our assets and liabilities that are measured at fair value on a recurring basis for the periods presented (in thousands):


	As of March 31, 2020
	Level I		Level II		Level III		Total
Cash equivalents		56,078		—		—		56,078
Marketable securities		—		6,293		—		6,293
Total assets	$	56,078	$	6,293	$	—	$	62,371
Warrant liability		—		—		3,547		3,547
Total liabilities	$	—	$	—	$	3,547	$	3,547


	As of December 31, 2019
	Level I		Level II		Level III		Total
Cash equivalents		56,544		—		—		56,544
Marketable securities		—		21,072		—		21,072
Total assets	$	56,544	$	21,072	$	—	$	77,616
Warrant liability		—		—		4,127		4,127
Total liabilities	$	—	$	—	$	4,127	$	4,127

The following table presents a reconciliation of our level 3 warrant liability (in thousands):


		As of March 31, 2020
Balance as of December 31, 2019	$	4,127
Unrealized gain on fair value of warrants for three months ended March 31, 2020		(580)
Balance as of March 31, 2020	$	3,547

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

XML 33 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.1 html 97 296 1 false 39 0 false 9 false false R1.htm 00090 - Document - Document and Entity Information Sheet http://www.strongbridgebio.com/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00100 - Statement - Consolidated Balance Sheets Sheet http://www.strongbridgebio.com/role/StatementConsolidatedBalanceSheets Consolidated Balance Sheets Statements 2 false false R3.htm 00105 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://www.strongbridgebio.com/role/StatementConsolidatedBalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00200 - Statement - Consolidated Statements of Operations and Comprehensive Loss Sheet http://www.strongbridgebio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss Consolidated Statements of Operations and Comprehensive Loss Statements 4 false false R5.htm 00300 - Statement - Consolidated Statement of Stockholders??? Equity Sheet http://www.strongbridgebio.com/role/StatementConsolidatedStatementOfStockholdersEquity Consolidated Statement of Stockholders??? Equity Statements 5 false false R6.htm 00400 - Statement - Consolidated Statements of Cash Flow Sheet http://www.strongbridgebio.com/role/StatementConsolidatedStatementsOfCashFlow Consolidated Statements of Cash Flow Statements 6 false false R7.htm 10101 - Disclosure - Organization Sheet http://www.strongbridgebio.com/role/DisclosureOrganization Organization Notes 7 false false R8.htm 10201 - Disclosure - Summary of significant accounting policies and basis of presentation Sheet http://www.strongbridgebio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentation Summary of significant accounting policies and basis of presentation Notes 8 false false R9.htm 10301 - Disclosure - Revenue recognition Sheet http://www.strongbridgebio.com/role/DisclosureRevenueRecognition Revenue recognition Notes 9 false false R10.htm 10401 - Disclosure - Fair value measurement Sheet http://www.strongbridgebio.com/role/DisclosureFairValueMeasurement Fair value measurement Notes 10 false false R11.htm 10501 - Disclosure - Marketable securities Sheet http://www.strongbridgebio.com/role/DisclosureMarketableSecurities Marketable securities Notes 11 false false R12.htm 10601 - Disclosure - Intangible assets and goodwill Sheet http://www.strongbridgebio.com/role/DisclosureIntangibleAssetsAndGoodwill Intangible assets and goodwill Notes 12 false false R13.htm 10701 - Disclosure - Accrued and other current liabilities Sheet http://www.strongbridgebio.com/role/DisclosureAccruedAndOtherCurrentLiabilities Accrued and other current liabilities Notes 13 false false R14.htm 10801 - Disclosure - Commitments and contingencies Sheet http://www.strongbridgebio.com/role/DisclosureCommitmentsAndContingencies Commitments and contingencies Notes 14 false false R15.htm 10901 - Disclosure - Income taxes Sheet http://www.strongbridgebio.com/role/DisclosureIncomeTaxes Income taxes Notes 15 false false R16.htm 11001 - Disclosure - Warrants Sheet http://www.strongbridgebio.com/role/DisclosureWarrants Warrants Notes 16 false false R17.htm 11101 - Disclosure - Stock-based compensation Sheet http://www.strongbridgebio.com/role/DisclosureStockBasedCompensation Stock-based compensation Notes 17 false false R18.htm 20202 - Disclosure - Summary of significant accounting policies and basis of presentation (Policies) Sheet http://www.strongbridgebio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentationPolicies Summary of significant accounting policies and basis of presentation (Policies) Policies 18 false false R19.htm 30203 - Disclosure - Summary of significant accounting policies and basis of presentation (Tables) Sheet http://www.strongbridgebio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentationTables Summary of significant accounting policies and basis of presentation (Tables) Tables http://www.strongbridgebio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentation 19 false false R20.htm 30403 - Disclosure - Fair value measurement (Tables) Sheet http://www.strongbridgebio.com/role/DisclosureFairValueMeasurementTables Fair value measurement (Tables) Tables http://www.strongbridgebio.com/role/DisclosureFairValueMeasurement 20 false false R21.htm 30503 - Disclosure - Marketable securities (Tables) Sheet http://www.strongbridgebio.com/role/DisclosureMarketableSecuritiesTables Marketable securities (Tables) Tables http://www.strongbridgebio.com/role/DisclosureMarketableSecurities 21 false false R22.htm 30603 - Disclosure - Intangible assets and goodwill (Tables) Sheet http://www.strongbridgebio.com/role/DisclosureIntangibleAssetsAndGoodwillTables Intangible assets and goodwill (Tables) Tables http://www.strongbridgebio.com/role/DisclosureIntangibleAssetsAndGoodwill 22 false false R23.htm 30703 - Disclosure - Accrued and other current liabilities (Tables) Sheet http://www.strongbridgebio.com/role/DisclosureAccruedAndOtherCurrentLiabilitiesTables Accrued and other current liabilities (Tables) Tables http://www.strongbridgebio.com/role/DisclosureAccruedAndOtherCurrentLiabilities 23 false false R24.htm 31003 - Disclosure - Warrants (Tables) Sheet http://www.strongbridgebio.com/role/DisclosureWarrantsTables Warrants (Tables) Tables http://www.strongbridgebio.com/role/DisclosureWarrants 24 false false R25.htm 31103 - Disclosure - Stock-based compensation (Tables) Sheet http://www.strongbridgebio.com/role/DisclosureStockBasedCompensationTables Stock-based compensation (Tables) Tables http://www.strongbridgebio.com/role/DisclosureStockBasedCompensation 25 false false R26.htm 40101 - Disclosure - Organization - Products (Details) Sheet http://www.strongbridgebio.com/role/DisclosureOrganizationProductsDetails Organization - Products (Details) Details 26 false false R27.htm 40102 - Disclosure - Organization - Sale of subsidiary (Details) Sheet http://www.strongbridgebio.com/role/DisclosureOrganizationSaleOfSubsidiaryDetails Organization - Sale of subsidiary (Details) Details 27 false false R28.htm 40103 - Disclosure - Organization - Liquidity (Details) Sheet http://www.strongbridgebio.com/role/DisclosureOrganizationLiquidityDetails Organization - Liquidity (Details) Details 28 false false R29.htm 40201 - Disclosure - Summary of significant accounting policies and basis of presentation - Leases (Details) Sheet http://www.strongbridgebio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentationLeasesDetails Summary of significant accounting policies and basis of presentation - Leases (Details) Details http://www.strongbridgebio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentationTables 29 false false R30.htm 40202 - Disclosure - Summary of significant accounting policies and basis of presentation - Marketable securities and Segment information (Details) Sheet http://www.strongbridgebio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentationMarketableSecuritiesAndSegmentInformationDetails Summary of significant accounting policies and basis of presentation - Marketable securities and Segment information (Details) Details 30 false false R31.htm 40203 - Disclosure - Summary of significant accounting policies and basis of presentation - Anti-dilutive securities (Details) Sheet http://www.strongbridgebio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentationAntiDilutiveSecuritiesDetails Summary of significant accounting policies and basis of presentation - Anti-dilutive securities (Details) Details 31 false false R32.htm 40301 - Disclosure - Revenue recognition - Product sales (Details) Sheet http://www.strongbridgebio.com/role/DisclosureRevenueRecognitionProductSalesDetails Revenue recognition - Product sales (Details) Details 32 false false R33.htm 40302 - Disclosure - Revenue recognition - Reserves (Details) Sheet http://www.strongbridgebio.com/role/DisclosureRevenueRecognitionReservesDetails Revenue recognition - Reserves (Details) Details 33 false false R34.htm 40401 - Disclosure - Fair value measurement - Assets and liabilities (Details) Sheet http://www.strongbridgebio.com/role/DisclosureFairValueMeasurementAssetsAndLiabilitiesDetails Fair value measurement - Assets and liabilities (Details) Details 34 false false R35.htm 40402 - Disclosure - Fair value measurement - Level 3 (Details) Sheet http://www.strongbridgebio.com/role/DisclosureFairValueMeasurementLevel3Details Fair value measurement - Level 3 (Details) Details 35 false false R36.htm 40501 - Disclosure - Marketable securities (Details) Sheet http://www.strongbridgebio.com/role/DisclosureMarketableSecuritiesDetails Marketable securities (Details) Details http://www.strongbridgebio.com/role/DisclosureMarketableSecuritiesTables 36 false false R37.htm 40601 - Disclosure - Intangible asset and goodwill - Components (Details) Sheet http://www.strongbridgebio.com/role/DisclosureIntangibleAssetAndGoodwillComponentsDetails Intangible asset and goodwill - Components (Details) Details 37 false false R38.htm 40602 - Disclosure - Intangible asset and goodwill - Asset purchase (Details) Sheet http://www.strongbridgebio.com/role/DisclosureIntangibleAssetAndGoodwillAssetPurchaseDetails Intangible asset and goodwill - Asset purchase (Details) Details 38 false false R39.htm 40701 - Disclosure - Accrued and other current liabilities (Details) Sheet http://www.strongbridgebio.com/role/DisclosureAccruedAndOtherCurrentLiabilitiesDetails Accrued and other current liabilities (Details) Details http://www.strongbridgebio.com/role/DisclosureAccruedAndOtherCurrentLiabilitiesTables 39 false false R40.htm 40801 - Disclosure - Commitments and contingencies - Commitments to Taro (Details) Sheet http://www.strongbridgebio.com/role/DisclosureCommitmentsAndContingenciesCommitmentsToTaroDetails Commitments and contingencies - Commitments to Taro (Details) Details 40 false false R41.htm 40901 - Disclosure - Income taxes (Details) Sheet http://www.strongbridgebio.com/role/DisclosureIncomeTaxesDetails Income taxes (Details) Details http://www.strongbridgebio.com/role/DisclosureIncomeTaxes 41 false false R42.htm 41001 - Disclosure - Warrants (Details) Sheet http://www.strongbridgebio.com/role/DisclosureWarrantsDetails Warrants (Details) Details http://www.strongbridgebio.com/role/DisclosureWarrantsTables 42 false false R43.htm 41101 - Disclosure - Stock-based compensation - General (Details) Sheet http://www.strongbridgebio.com/role/DisclosureStockBasedCompensationGeneralDetails Stock-based compensation - General (Details) Details 43 false false R44.htm 41102 - Disclosure - Stock-based compensation - Stock options activity (Details) Sheet http://www.strongbridgebio.com/role/DisclosureStockBasedCompensationStockOptionsActivityDetails Stock-based compensation - Stock options activity (Details) Details 44 false false R45.htm 41103 - Disclosure - Stock-based compensation - Stock-based compensation expense (Details) Sheet http://www.strongbridgebio.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails Stock-based compensation - Stock-based compensation expense (Details) Details 45 false false R46.htm 41104 - Disclosure - Stock-based compensation - Fair value assumptions (Details) Sheet http://www.strongbridgebio.com/role/DisclosureStockBasedCompensationFairValueAssumptionsDetails Stock-based compensation - Fair value assumptions (Details) Details 46 false false R47.htm 41105 - Disclosure - Stock-based compensation - Restricted stock units (Details) Sheet http://www.strongbridgebio.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails Stock-based compensation - Restricted stock units (Details) Details 47 false false All Reports Book All Reports sbbp-20200331.xml sbbp-20200331.xsd sbbp-20200331_cal.xml sbbp-20200331_def.xml sbbp-20200331_lab.xml sbbp-20200331_pre.xml http://fasb.org/us-gaap/2019-01-31 http://xbrl.sec.gov/dei/2019-01-31 http://fasb.org/srt/2019-01-31 true true ZIP 34 0001558370-20-005292-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001558370-20-005292-xbrl.zip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end XML 35 R33.htm IDEA: XBRL DOCUMENT v3.20.1

Revenue recognition - Reserves (Details)
$ in Millions
3 Months Ended

Mar. 31, 2020

USD ($)

Reserve for returns $ 0.0

Percentage of patient’s cost of branded prescription drugs related to the Medicare Part D Coverage Gap for which manufacturers of pharmaceutical products are responsible 70.00%

Maximum

Temporary supply period 60 days

Financial need period 12 months

X

- Definition
Represents the percentage of patient’s cost of branded prescription drugs related to the Medicare Part D Coverage Gap for which manufacturers of pharmaceutical products are responsible.
+ References
No definition available.
+ Details

Name: sbbp_PercentageOfPatientsCostOfBrandedPrescriptionDrugsRelatedToMedicarePartDCoverageGap

Namespace Prefix: sbbp_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Represent maximum period over which entity may provide free product to patient under financial assistance programs, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
No definition available.
+ Details

Name: sbbp_RevenueFinancialNeed

Namespace Prefix: sbbp_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents maximum period over which entity may provide free product to patient while determining insurance coverage under temporary assistance programs, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
No definition available.
+ Details

Name: sbbp_RevenueTemporarySupply

Namespace Prefix: sbbp_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of liability for consideration received or receivable from customer which is not included in transaction price, when consideration is expected to be refunded to customer.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 55
-Paragraph 27
-URI http://asc.fasb.org/extlink&oid=118944142&loc=SL49130611-203046-203046
+ Details

Name: us-gaap_ContractWithCustomerRefundLiability

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: srt_RangeAxis=srt_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 36 R37.htm IDEA: XBRL DOCUMENT v3.20.1

Intangible asset and goodwill - Components (Details) - USD ($)
$ in Thousands
3 Months Ended

Mar. 31, 2020

Mar. 31, 2019

Intangible asset and goodwill

Finite-lived intangible assets, Amortization $ (1,256) $ (1,256)

Goodwill, Beginning of Period 7,256

Goodwill, End of Period 7,256

Total, Beginning of Period 32,366

Total, End of Period 31,111

Keveyis

Intangible asset and goodwill

Finite-lived intangible assets, Beginning of Period 25,110

Finite-lived intangible assets, Amortization (1,256)

Finite-lived intangible assets, End of Period $ 23,855

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: sbbp_IntangibleAssetsAndGoodwillLineItems

Namespace Prefix: sbbp_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274
+ Details

Name: us-gaap_AmortizationOfIntangibleAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=77989000&loc=SL49117168-202975

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266
+ Details

Name: us-gaap_Goodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Carrying amount of finite-lived intangible assets, indefinite-lived intangible assets and goodwill. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Intangible assets are assets, not including financial assets, lacking physical substance.
+ References
No definition available.
+ Details

Name: us-gaap_IntangibleAssetsNetIncludingGoodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: srt_ProductOrServiceAxis=sbbp_KeveyisMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 37 R24.htm IDEA: XBRL DOCUMENT v3.20.1

Warrants (Tables)
3 Months Ended

Mar. 31, 2020

Warrants

Schedule of warrants







Warrants

Outstanding

Exercise



Expiration



Warrants



Warrants

March 31,

Classification

Price

Date

Issued

Exercised

2020

Warrants in connection with private equity placement



Liability



$

2.50



6/28/2022



7,000,000

(1,970,000)

5,030,000

Warrants in connection with Horizon and Oxford loan agreement

Equity

$

2.45

12/28/2026

428,571

(267,857)

160,714

Warrants in connection with CRG loan agreement

Equity

$

7.37

7/14/2024

394,289

—

394,289

Warrants in connection with CRG loan amendment in January 2018

Equity

$

10.00

1/16/2025

1,248,250

—

1,248,250

9,071,110

6,833,253

X

- Definition
Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(i))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 50
-Section S99
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775
+ Details

Name: us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_WarrantsAndRightsNoteDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 38 R20.htm IDEA: XBRL DOCUMENT v3.20.1

Fair value measurement (Tables)
3 Months Ended

Mar. 31, 2020

Fair value measurement

Schedule of fair value of financial assets by level

The following table presents our assets and liabilities that are measured at fair value on a recurring basis for the periods presented (in thousands):

As of March 31, 2020

Level I

Level II

Level III

Total

Cash equivalents

56,078

—

—

56,078

Marketable securities

—

6,293

—

6,293

Total assets

$

56,078

$

6,293

$

—

$

62,371

Warrant liability

—

—

3,547

3,547

Total liabilities

$

—

$

—

$

3,547

$

3,547

As of December 31, 2019

Level I

Level II

Level III

Total

Cash equivalents

56,544

—

—

56,544

Marketable securities

—

21,072

—

21,072

Total assets

$

56,544

$

21,072

$

—

$

77,616

Warrant liability

—

—

4,127

4,127

Total liabilities

$

—

$

—

$

4,127

$

4,127

Schedule of reconciliation of level 3 Warrant liability

The following table presents a reconciliation of our level 3 warrant liability (in thousands):



As of March 31, 2020

Balance as of December 31, 2019

$

4,127

Unrealized gain on fair value of warrants for three months ended March 31, 2020

(580)

Balance as of March 31, 2020

$

3,547

X

- Definition
Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2C
-URI http://asc.fasb.org/extlink&oid=117815213&loc=SL7498348-110258

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (bb)
-URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258
+ Details

Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_FairValueDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258
+ Details

Name: us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 39 R8.htm IDEA: XBRL DOCUMENT v3.20.1

Summary of significant accounting policies and basis of presentation
3 Months Ended

Mar. 31, 2020

Summary of significant accounting policies and basis of presentation

Summary of significant accounting policies and basis of presentation

2. Summary of significant accounting policies and basis of presentation

Basis of presentation

These unaudited consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States (“U.S. GAAP”). The unaudited consolidated financial statements reflect all adjustments, which include only normal recurring adjustments that are, in the opinion of management, necessary to present a fair statement of the operating results and financial position for the periods presented.

The preparation of the unaudited consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect reported amounts and disclosures in the consolidated financial statements. Actual results could differ from those estimates. Results for the three months ended March 31, 2020 are not necessarily indicative of the results that may be expected for the year ending December 31, 2020.

These unaudited consolidated financial statements should be read in conjunction with the accounting policies and notes to the audited consolidated financial statements included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2019 filed with the U.S. Securities and Exchange Commission on February 28, 2020 (the “2019 Annual Report”). Our significant accounting policies are described in Note 2 of the notes to the audited consolidated financial statements included in our 2019 Annual Report. Since the date of those financial statements, there have been no changes to our significant accounting policies.

Leases

We account for leases in accordance with Accounting Standards Codification Topic 842, Leases, (“ASC 842”). We determine if an arrangement is a lease at contract inception. A lease exists when a contract conveys to us the right to control the use of identified property, plant, or equipment for a period of time in exchange for consideration. The definition of a lease embodies two conditions: (1) there is an identified asset in the contract that is land or a depreciable asset (i.e., property, plant, and equipment), and (2) we have the right to control the use of the identified asset.

Operating leases where we are the lessee are included in Right of use (“ROU”) assets and Other current liabilities and Other long-term liabilities on our Consolidated Balance Sheets. The lease liabilities are initially and subsequently measured at the present value of the unpaid lease payments at the lease commencement date.

Key estimates and judgments include how we determined (1) the discount rate we use to discount the unpaid lease payments to present value, (2) lease term and (3) lease payments.

ASC 842 requires a lessee to discount its unpaid lease payments using the interest rate implicit in the lease or, if that rate cannot be readily determined, its incremental borrowing rate. Because our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. Our incremental borrowing rate for a lease is the rate of interest we would have to pay on a collateralized basis to borrow an amount equal to the lease payments under similar terms.

The lease term for all of our leases includes the noncancellable period of the lease. Lease payments included in the measurement of the lease asset or liability are comprised of our fixed payments.

The ROU asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for lease payments made at or before the lease commencement date less any lease incentives received.

For operating leases, the ROU asset is subsequently measured throughout the lease term at the carrying amount of the lease liability, plus (minus) any prepaid (accrued) lease payments, less the unamortized balance of lease incentives received. Lease expense for lease payments is recognized on a straight-line basis over the lease term.

We monitor for events or changes in circumstances that require a reassessment of a lease. If a reassessment results in the remeasurement of a lease liability, a corresponding adjustment is made to the carrying amount of the corresponding ROU asset unless doing so would reduce the carrying amount of the ROU asset to an amount less than zero. In that case, the amount of the adjustment that would result in a negative ROU asset balance is recorded in profit or loss.

We have elected not to recognize ROU assets and lease liabilities for all short-term leases that have a lease term of 12 months or less. We recognize the lease payments associated with our short-term leases as an expense on a straight-line basis over the lease term. Variable lease payments associated with these leases are recognized and presented in the same manner as for all our other leases.

We adopted ASC 842 using a modified retrospective transition approach as of the effective date, as permitted by the amendments in ASU 2018-11. As a result, we were not required to adjust our comparative period financial information for effects of the standard or make the new required lease disclosures for periods before the date of adoption (i.e., January 1, 2019). We have elected to adopt the package of transition practical expedients and, therefore, have not reassessed (1) whether existing or expired contracts contain a lease, (2) lease classification for existing or expired leases or (3) the accounting for initial direct costs that were previously capitalized. We did not elect the practical expedient to use hindsight for leases existing at the adoption date. Further, we do not expect the amendments in ASU 2018-01: Land Easement Practical Expedient to have an effect on us because we do not enter into land easement arrangements.

Cash, cash equivalents and marketable securities

We consider all short‑term highly liquid investments with an original maturity at the date of purchase of three months or less to be cash equivalents. Cash and cash equivalents consist of account balances at banks and money market accounts, respectively.

We invest our excess cash balances in marketable securities of highly rated financial institutions. We seek to diversify our investments and limit the amount of investment concentrations for individual institutions, maturities and investment types. We classify marketable debt securities as available-for-sale and, accordingly, record such securities at fair value. We classify these securities as current assets as these investments are intended to be available to us for use in funding current operations. There were no marketable securities with a maturity of greater than one year as of March 31, 2020.

Unrealized gains and losses on marketable debt securities are recorded as a separate component of accumulated other comprehensive income (loss) included in stockholders’ equity.

Segment information

Operating segments are identified as components of an enterprise for which separate discrete financial information is available for evaluation by the chief operating decision maker, or decision making group, in making decisions on how to allocate resources and assess performance. We view our operations and manage our business in one operating segment.

Net loss per share

Basic net loss per share is calculated by dividing the net loss attributable to shareholders by the weighted average number of ordinary shares outstanding during the period. Diluted net loss per share is calculated by dividing the net loss attributable to shareholders by the weighted‑average number of ordinary shares outstanding for the period, including any dilutive effect from outstanding stock options or other equity-based awards. Shares used in the diluted net loss per share calculations exclude anti‑dilutive ordinary share equivalents, which currently consist of outstanding stock options, unvested restricted stock units (“RSUs”) and equity-classified warrants.

The following potentially dilutive securities have been excluded from the computations of diluted weighted average shares outstanding as of March 31, 2020 and 2019, as they would be anti-dilutive:

March 31,

2020

2019

Warrants

1,803,253

6,833,253

Stock options issued and outstanding



10,334,368

10,205,851

Unvested RSUs

925,800

758,850

Recent accounting pronouncements – not yet adopted

In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments. ASU 2016-13 requires an entity to measure and recognize expected credit losses for certain financial instruments, including trade receivables, as an allowance that reflects the entity's current estimate of credit losses expected to be incurred. For available-for-sale debt securities with unrealized losses, the standard requires allowances to be recorded through net income instead of directly reducing the amortized cost of the investment under the current other-than-temporary impairment model. The standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019 for SEC filers, excluding smaller reporting companies, who have until fiscal years beginning after December 15, 2022. We do not expect the adoption of this standard to have a significant impact on our financial statements or internal controls.

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-URI http://asc.fasb.org/topic&trid=2122149

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-URI http://asc.fasb.org/topic&trid=2197479

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-URI http://asc.fasb.org/topic&trid=2122369

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-URI http://asc.fasb.org/topic&trid=2134479
+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 40 R28.htm IDEA: XBRL DOCUMENT v3.20.1

Organization - Liquidity (Details)
$ in Millions
3 Months Ended

Mar. 31, 2020

USD ($)

Liquidity

Cash, cash equivalents and marketable securities $ 62.8

Substantial doubt about going concern, within one year false

X

- References
No definition available.
+ Details

Name: sbbp_LiquidityAbstract

Namespace Prefix: sbbp_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CashCashEquivalentsAndShortTermInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Indicates (true false) whether there was substantial doubt about ability to continue as going concern within one year after date financial statements are issued.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 40
-Section 50
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=116846462&loc=SL51888449-203568
+ Details

Name: us-gaap_SubstantialDoubtAboutGoingConcernWithinOneYear

Namespace Prefix: us-gaap_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

XML 41 R4.htm IDEA: XBRL DOCUMENT v3.20.1

Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
3 Months Ended

Mar. 31, 2020

Mar. 31, 2019

Revenues:

Total revenues $ 6,674 $ 4,343

Cost and expenses:

Cost of sales (excluding amortization of intangible asset) 969 813

Selling, general and administrative 10,403 12,100

Research and development 7,552 6,583

Amortization of intangible asset 1,256 1,256

Total cost and expenses 20,180 20,752

Operating loss (13,506) (16,409)

Other income (expenses), net:

Unrealized gain (loss) on fair value of warrants 580 (1,820)

Income from field services agreement 2,016

Expense from field services agreement (2,229)

Other income, net 228 685

Total other income (expenses), net 808 (1,348)

Loss before income taxes (12,698) (17,757)

Income tax expense 0 (677)

Net loss (12,698) (18,434)

Unrealized gain on marketable securities 3

Comprehensive loss (12,695) (18,434)

Net loss attributable to ordinary shareholders:

Basic (12,698) (18,434)

Diluted $ (13,278) $ (18,434)

Net loss per share attributable to ordinary shareholders:

Basic (in dollars per share) $ (0.23) $ (0.34)

Diluted (in dollars per share) $ (0.24) $ (0.34)

Weighted-average shares used in computing net loss per share attributable to ordinary shareholders:

Basic (in shares) 54,231,024 54,155,034

Diluted (in shares) 54,444,681 54,155,034

Product

Revenues:

Total revenues $ 6,663 $ 4,333

Royalty

Revenues:

Total revenues $ 11 $ 10

X

- References
No definition available.
+ Details

Name: sbbp_NetIncomeLossAvailableToCommonStockholdersBasicAndDilutedAbstract

Namespace Prefix: sbbp_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of expense from field service reimbursement.
+ References
No definition available.
+ Details

Name: sbbp_NonoperatingExpenseExpenseFromFieldServiceReimbursement

Namespace Prefix: sbbp_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of income from field service reimbursement.
+ References
No definition available.
+ Details

Name: sbbp_NonoperatingIncomeIncomeFromFieldServiceReimbursement

Namespace Prefix: sbbp_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274
+ Details

Name: us-gaap_AmortizationOfIntangibleAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of unrealized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563
+ Details

Name: us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=118930883&loc=d3e557-108580

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580
+ Details

Name: us-gaap_ComprehensiveIncomeNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Cost of product sold and service rendered, excluding depreciation, depletion, and amortization.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(2)(a))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(2)(d))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Total costs of sales and operating expenses for the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03)
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_CostsAndExpenses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=117327953&loc=d3e4984-109258

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256
+ Details

Name: us-gaap_EarningsPerShareBasic

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareBasicAndDilutedAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=117327953&loc=d3e4984-109258

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263
+ Details

Name: us-gaap_EarningsPerShareDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of expense (income) related to adjustment to fair value of warrant liability.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 480
-SubTopic 10
-Section 25
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875
+ Details

Name: us-gaap_FairValueAdjustmentOfWarrants

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 940
-SubTopic 20
-Section 25
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(10))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(8))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(15))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260
+ Details

Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (h)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 20
-Section 45
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324
+ Details

Name: us-gaap_IncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1377-109256
+ Details

Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1505-109256

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1377-109256
+ Details

Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.7)
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_NonoperatingIncomeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NonoperatingIncomeExpenseAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OperatingExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The net result for the period of deducting operating expenses from operating revenues.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of income (expense) related to nonoperating activities, classified as other.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.9)
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_OtherNonoperatingIncomeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373
+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130543-203045

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045
+ Details

Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_RevenuesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section 30
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=68048583&loc=d3e3636-108311

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.4)
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_SellingGeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1505-109256
+ Details

Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1448-109256

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: srt_ProductOrServiceAxis=us-gaap_ProductMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_ProductOrServiceAxis=us-gaap_RoyaltyMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 43 R41.htm IDEA: XBRL DOCUMENT v3.20.1

Income taxes (Details) - USD ($)
$ in Thousands
3 Months Ended

Mar. 31, 2020

Mar. 31, 2019

Components of income tax expense (benefit)

Income tax expense $ 0 $ 677

X

- Definition
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (h)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 20
-Section 45
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324
+ Details

Name: us-gaap_IncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 44 R45.htm IDEA: XBRL DOCUMENT v3.20.1

Stock-based compensation - Stock-based compensation expense (Details) - USD ($)
$ in Thousands
3 Months Ended

Mar. 31, 2020

Mar. 31, 2019

Stock-based compensation expense

Total stock-based compensation $ 1,751 $ 2,323

Stock options

Stock-based compensation expense

Total unrecognized compensation expense $ 12,400

Estimated weighted average period over which expense is expected to be recognized 2 years 10 months 21 days

Selling, general and administrative

Stock-based compensation expense

Total stock-based compensation $ 1,270 1,811

Research and development

Stock-based compensation expense

Total stock-based compensation $ 481 $ 512

X

- Definition
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14.F)
-URI http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (h)(1)(i)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_AllocatedShareBasedCompensationExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cost to be recognized for option under share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 46 R39.htm IDEA: XBRL DOCUMENT v3.20.1

Accrued and other current liabilities (Details) - USD ($)
$ in Thousands

Mar. 31, 2020

Dec. 31, 2019

Accrued and other current liabilities

Consulting and professional fees $ 5,640 $ 4,335

Supply agreement - current portion 4,391 2,773

Accrued sales allowances 2,229 2,990

Employee compensation 2,078 4,452

Accrued taxes 1,892 1,892

Severance 1,088 2,968

Lease liability - current portion 384 374

Accrued royalties 302 806

Other 509 372

Total accrued liabilities $ 18,513 $ 20,962

X

- Definition
Carrying value as of the balance sheet date of obligations incurred through that date and payable in connection with supply agreement. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
No definition available.
+ Details

Name: sbbp_AccruedLiabilitiesSupplyAgreementCurrent

Namespace Prefix: sbbp_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of obligations incurred through that date for sales allowances (due within one year or within the normal operating cycle if longer).
+ References
No definition available.
+ Details

Name: sbbp_AccruedSalesAllowanceCurrent

Namespace Prefix: sbbp_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of the obligations incurred through that date and payable for severance. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
No definition available.
+ Details

Name: sbbp_AccruedSeveranceCurrent

Namespace Prefix: sbbp_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6911-107765

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6935-107765
+ Details

Name: us-gaap_AccruedProfessionalFeesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6911-107765

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6935-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccruedRoyaltiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_EmployeeRelatedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977
+ Details

Name: us-gaap_OperatingLeaseLiabilityCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6911-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e7018-107765

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6935-107765
+ Details

Name: us-gaap_OtherAccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19,20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_TaxesPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 47 R31.htm IDEA: XBRL DOCUMENT v3.20.1

Summary of significant accounting policies and basis of presentation - Anti-dilutive securities (Details) - shares
3 Months Ended

Mar. 31, 2020

Mar. 31, 2019

Warrant liability

Net loss per share

Anti-dilutive shares of common stock (in shares) 1,803,253 6,833,253

Stock options

Net loss per share

Anti-dilutive shares of common stock (in shares) 10,334,368 10,205,851

RSUs

Net loss per share

Anti-dilutive shares of common stock (in shares) 925,800 758,850

X

- Definition
Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 48 R35.htm IDEA: XBRL DOCUMENT v3.20.1

Fair value measurement - Level 3 (Details) - Warrant liability
$ in Thousands
3 Months Ended

Mar. 31, 2020

USD ($)

Reconciliation of level 3:

Balance at beginning of period $ 4,127

Unrealized gain on fair value of warrants (580)

Balance at end of period $ 3,547

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258
+ Details

Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258
+ Details

Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_FairValueByLiabilityClassAxis=us-gaap_WarrantMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

EXCEL 49 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 50 R16.htm IDEA: XBRL DOCUMENT v3.20.1

Warrants
3 Months Ended

Mar. 31, 2020

Warrants

Warrants

10. Warrants

Warrants

Our outstanding warrants as of March 31, 2020 are as follows:







Warrants

Outstanding

Exercise



Expiration



Warrants



Warrants

March 31,

Classification

Price

Date

Issued

Exercised

2020

Warrants in connection with private equity placement



Liability



$

2.50



6/28/2022



7,000,000

(1,970,000)

5,030,000

Warrants in connection with Horizon and Oxford loan agreement

Equity

$

2.45

12/28/2026

428,571

(267,857)

160,714

Warrants in connection with CRG loan agreement

Equity

$

7.37

7/14/2024

394,289

—

394,289

Warrants in connection with CRG loan amendment in January 2018

Equity

$

10.00

1/16/2025

1,248,250

—

1,248,250

9,071,110

6,833,253

X

- Definition
The entire disclosure of warrants issued and outstanding.
+ References
No definition available.
+ Details

Name: sbbp_WarrantsNoteDisclosureTextBlock

Namespace Prefix: sbbp_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_WarrantsAndRightsNoteDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 51 R12.htm IDEA: XBRL DOCUMENT v3.20.1

Intangible assets and goodwill
3 Months Ended

Mar. 31, 2020

Intangible asset and goodwill

Intangible assets and goodwill

6. Intangible asset and goodwill

The following represents the balance of our intangible asset and goodwill as follows (in thousands):

As of March 31, 2020

Beginning of Period

Amortization

End of Period

Keveyis

$

25,110

$

(1,256)

$

23,855

Goodwill

7,256

—

7,256

Total

$

32,366

$

(1,256)

$

31,111

Our finite-lived intangible asset consists of acquired developed product rights obtained from our acquisition of Keveyis (dichlorphenamide) from a subsidiary of Taro Pharmaceutical Industries Ltd. (“Taro”).

Pursuant to the terms of the Asset Purchase Agreement and Supply Agreement that we entered into with Taro in December 2016, we paid Taro an upfront payment in two installments of $1 million in December 2016 and $7.5 million in March 2017. We concluded that the supply price payable by us exceeds fair value and, therefore, used a discounted cash flow method with a probability assumption to value the payments in excess of fair value at $29.3 million, for which we have recorded an intangible asset and corresponding liability. This liability is being reduced as we purchase inventory over the term of the Supply Agreement that we entered into with Taro. In addition, we incurred transaction costs of $2.4 million. The transaction resulted in the recording of an intangible asset of $40.2 million. This asset is being amortized over an eight-year period using the straight-line method.

We recorded amortization expense of $1.3 million the three months ended March 31, 2020 and three months ended March 31, 2019, respectively.

X

- References
No definition available.
+ Details

Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for goodwill and intangible assets.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-URI http://asc.fasb.org/topic&trid=2144416
+ Details

Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 52 R30.htm IDEA: XBRL DOCUMENT v3.20.1

Summary of significant accounting policies and basis of presentation - Marketable securities and Segment information (Details)
$ in Millions
3 Months Ended

Mar. 31, 2020

USD ($)

segment

Segment information

Marketable securities, noncurrent | $ $ 0.0

Number of operating segments | segment 1

X

- Definition
Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 30
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=118942338&loc=SL82898722-210454

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=118954083&loc=d3e26626-111562
+ Details

Name: us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.
+ References
No definition available.
+ Details

Name: us-gaap_NumberOfOperatingSegments

Namespace Prefix: us-gaap_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_SegmentReportingAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 53 R34.htm IDEA: XBRL DOCUMENT v3.20.1

Fair value measurement - Assets and liabilities (Details) - USD ($)
$ in Thousands

Mar. 31, 2020

Dec. 31, 2019

Assets

Marketable securities $ 6,293 $ 21,072

Liabilities

Warrant liability 3,547 4,127

Recurring

Assets

Cash equivalents 56,078 56,544

Marketable securities 6,293 21,072

Total Assets 62,371 77,616

Liabilities

Warrant liability 3,547 4,127

Total liabilities 3,547 4,127

Recurring | Level I

Assets

Cash equivalents 56,078 56,544

Total Assets 56,078 56,544

Recurring | Level II

Assets

Marketable securities 6,293 21,072

Total Assets 6,293 21,072

Recurring | Level III

Liabilities

Warrant liability 3,547 4,127

Total liabilities $ 3,547 $ 4,127

X

- Definition
Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258
+ Details

Name: us-gaap_AssetsFairValueDisclosure

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_AssetsFairValueDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 30
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=118942338&loc=SL82898722-210454

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=118954083&loc=d3e26626-111562
+ Details

Name: us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ References
No definition available.
+ Details

Name: us-gaap_CashAndCashEquivalentsFairValueDisclosure

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Fair value of financial and nonfinancial obligations.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258
+ Details

Name: us-gaap_LiabilitiesFairValueDisclosure

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_LiabilitiesFairValueDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(i))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_WarrantsAndRightsOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 54 R38.htm IDEA: XBRL DOCUMENT v3.20.1

Intangible asset and goodwill - Asset purchase (Details) - Acquired product rights - Keveyis
$ in Millions
1 Months Ended

Mar. 31, 2017

USD ($)

Dec. 31, 2016

USD ($)

installment

In-process research and development and Goodwill

Number of installment payments | installment 2

Installment payment $ 7.5 $ 1.0

Payments in excess of fair value 29.3

Transaction costs 2.4

Acquired product rights $ 40.2

Estimated life 8 years

X

- Definition
Amount of direct costs of the asset acquisition including legal, accounting, and other costs incurred to consummate the transaction.
+ References
No definition available.
+ Details

Name: sbbp_AssetAcquisitionTransactionCosts

Namespace Prefix: sbbp_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: sbbp_IntangibleAssetsAndGoodwillLineItems

Namespace Prefix: sbbp_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents the number of installment payments.
+ References
No definition available.
+ Details

Name: sbbp_NumberOfInstallmentPayments

Namespace Prefix: sbbp_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: instant

X

- Definition
Amount of supply price payable using a discounted cash flow method to value payments.
+ References
No definition available.
+ Details

Name: sbbp_SupplyPricePayable

Namespace Prefix: sbbp_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
No definition available.
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetUsefulLife

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 928
-SubTopic 340
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585
+ Details

Name: us-gaap_PaymentsToAcquireIntangibleAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=sbbp_AcquiredDevelopedProductRightsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_ProductOrServiceAxis=sbbp_KeveyisMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 55 R17.htm IDEA: XBRL DOCUMENT v3.20.1

Stock-based compensation
3 Months Ended

Mar. 31, 2020

Stock-based compensation

Stock based compensation

11. Stock‑based compensation

Our board of directors has adopted the 2017 Inducement Plan (the “Inducement Plan”). The Inducement Plan provides for the grant of equity-based awards to new employees. The purpose of the Inducement Plan is to attract valued employees by offering them a greater stake in our success and a closer identity with us, and to encourage ownership of our ordinary shares by such employees. The Inducement Plan became effective on February 23, 2017. As of March 31, 2020, 1,374,528 shares are available for issuance pursuant to the Inducement Plan.

Our board of directors has adopted, and our shareholders have approved, the 2015 Equity Compensation Plan (the “2015 Plan”). The 2015 Plan provides for the grant of incentive stock options to our employees and any parent or subsidiary corporation’s employees, and for the grant of nonstatutory stock options, stock awards, and RSUs to our employees, directors and consultants and our parent or subsidiary corporations’ employees and consultants. The 2015 Plan became effective on September 3, 2015. As of March 31, 2020, 561,158 shares are available for issuance pursuant to the 2015 Plan.

Our board of directors has adopted, and our shareholders have approved, the Non‑Employee Director Equity Compensation Plan (the “Non‑Employee Director Plan”). The Non‑Employee Director Plan provides for the grant of nonstatutory stock options, stock awards, and RSUs to our non‑employee directors. The Non‑Employee Director Plan became effective on September 3, 2015. As of March 31, 2020, 271,029 shares are available for issuance pursuant to the Non‑Employee Director Plan.

A summary of our outstanding stock options as of March 31, 2020 is as follows:

Options Outstanding







Weighted-



Average

Weighted-

Remaining

Average

Contractual

Number of

Exercise

Term

Aggregate

Shares

Price

(Years)

Intrinsic Value

(in thousands)

Outstanding—January 1, 2020

9,192,684

$

6.58

5.96

$

164

Granted

2,393,000

$

2.97

Forfeited and cancelled

(1,133,316)

$

10.66

Exercised

—

$

—

Outstanding—March 31, 2020

10,452,368

$

5.31

2.01

$

104

Vested and exercisable—March 31, 2020

5,100,335

$

6.86

5.39

$

6

Stock‑based compensation expense

We recognized stock‑based compensation expense for employees and directors for stock options and RSUs as follows (in thousands):

Three Months Ended



March 31,

2020



2019

Selling, general and administrative

$

1,270

$

1,811

Research and development

481

512

Total stock-based compensation

$

1,751

$

2,323

As of March 31, 2020, the total unrecognized compensation expense related to unvested stock options is $12.4 million, which we expect to recognize over an estimated weighted‑average period of 2.89 years.

In determining the estimated fair value of our service-based awards, we use the Black‑Scholes option‑pricing model and assumptions discussed below. Each of these inputs is subjective and generally requires significant judgment. The fair value of our service-based awards that were granted during the years was estimated with the following assumptions:

Three Months Ended

March 31,



2020



2019

Expected term (in years)

6.07

6.09

Risk-free interest rate

1.47%-1.48%

2.47%-2.61%

Expected volatility

78.15%-78.21%

80.00%-80.85%

Dividend rate

—%

—%

Restricted stock units

We grant RSUs to employees and to members of our board of directors. RSUs that are granted to employees vest two years from the date of issuance, provided that the employee is employed by us on such vesting date. RSUs that are granted to directors, vest on the one-year anniversary of the grant date, provided that the director continues to serve as a member of the board of directors continuously from the grant date through such one-year anniversary. All RSUs will fully vest upon a change of control of our company. If and when the RSUs vest, we will issue one ordinary share for each whole RSU that has vested, subject to satisfaction of the employee’s or director’s tax withholding obligations. The RSUs will cease to be outstanding upon the issuance of ordinary shares upon vesting. We recorded expense, which is included in the stock-based compensation table above, of $0.5 million for the three months ended March 31, 2020 and 2019, respectively. As of March 31, 2020, the total unrecognized compensation expense related to unvested RSUs is $1.6 million, which we expect to recognize over an estimated weighted‑average period of 1.21 years.

A summary of our unvested RSUs as of March 31, 2020 is as follows:

Number of

Shares

Outstanding—January 1, 2020

791,350

Granted

212,650

Forfeited

(17,200)

Vested

(61,000)

Unvested—March 31, 2020

925,800

X

- Definition
The entire disclosure for share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-URI http://asc.fasb.org/topic&trid=2228938
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 56 R13.htm IDEA: XBRL DOCUMENT v3.20.1

Accrued and other current liabilities
3 Months Ended

Mar. 31, 2020

Accrued and other current liabilities

Accrued and other current liabilities

7. Accrued and other current liabilities

Accrued and other current liabilities consist of the following (in thousands):

March 31,

December 31,

2020

2019

Consulting and professional fees

$

5,640

$

4,335

Supply agreement - current portion

4,391

2,773

Accrued sales allowances

2,229

2,990

Employee compensation

2,078

4,452

Accrued taxes

1,892

1,892

Severance

1,088

2,968

Lease liability - current portion

384

374

Accrued royalties

302

806

Other

509

372

Total accrued liabilities

$

18,513

$

20,962

X

- Definition
The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19(a),20,24)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 57 R29.htm IDEA: XBRL DOCUMENT v3.20.1

Summary of significant accounting policies and basis of presentation - Leases (Details)

Jan. 01, 2019

Mar. 31, 2020

Recently issued accounting pronouncements

Operating Lease, Liability, Statement of Financial Position us-gaap:OtherLiabilitiesCurrent us-gaap:OtherLiabilitiesNoncurrent

Lease, Practical Expedients, Package true

Lease, Practical Expedient, Use of Hindsight false

ASU 2016-02

Recently issued accounting pronouncements

Change in Accounting Principle, Accounting Standards Update, Adopted true

Change in Accounting Principle, Accounting Standards Update, Transition Option Elected Modified Retrospective

New Accounting Pronouncement or Change in Accounting Principle, Prior Period Not Restated true

X

- Definition
Indicates (true false) whether accounting standards update was adopted.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794
+ Details

Name: us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted

Namespace Prefix: us-gaap_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: instant

X

- Definition
Indicates transition method applied for adoption of accounting standards update. Acceptable values are "Retrospective", "Prospective", "Modified Retrospective" and "Modified Prospective".
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794
+ Details

Name: us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateTransitionOptionElectedFixedList

Namespace Prefix: us-gaap_

Data Type: us-types:transitionOptionType

Balance Type: na

Period Type: instant

X

- Definition
Indicates (true false) whether practical expedient is elected to use hindsight in determining lease term and in assessing impairment of right-of-use asset.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 10
-Section 65
-Paragraph 1
-Subparagraph (j)
-URI http://asc.fasb.org/extlink&oid=119364159&loc=SL77916155-209984

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 10
-Section 65
-Paragraph 1
-Subparagraph (g)
-URI http://asc.fasb.org/extlink&oid=119364159&loc=SL77916155-209984
+ Details

Name: us-gaap_LeasePracticalExpedientUseOfHindsight

Namespace Prefix: us-gaap_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicates (true false) whether practical expedients are elected for not reassessing whether any expired or existing contract is or contains lease, lease classification for expired or existing lease, and initial direct cost for any existing lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 10
-Section 65
-Paragraph 1
-Subparagraph (j)
-URI http://asc.fasb.org/extlink&oid=119364159&loc=SL77916155-209984

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 10
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=119364159&loc=SL77916155-209984
+ Details

Name: us-gaap_LeasePracticalExpedientsPackage

Namespace Prefix: us-gaap_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicates (true false) whether prior period was not restated when there is change in accounting principle or adoption of new accounting pronouncement. Excludes correction of error.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(4)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 65
-Paragraph 4
-Subparagraph (d)(2)
-URI http://asc.fasb.org/extlink&oid=117331771&loc=SL75117418-158277
+ Details

Name: us-gaap_NewAccountingPronouncementOrChangeInAccountingPrinciplePriorPeriodNotRestated

Namespace Prefix: us-gaap_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicates line item in statement of financial position that includes operating lease liability.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=77888419&loc=SL77918631-209977
+ Details

Name: us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList

Namespace Prefix: us-gaap_

Data Type: srt-types:extensibleListItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 58 R1.htm IDEA: XBRL DOCUMENT v3.20.1

Document and Entity Information - shares
3 Months Ended

Mar. 31, 2020

May 01, 2020

Document and Entity Information [Abstract]

Document Type 10-Q

Document Period End Date Mar. 31, 2020

Entity Registrant Name STRONGBRIDGE BIOPHARMA plc

Entity Current Reporting Status Yes

Entity Interactive Data Current Yes

Entity Filer Category Accelerated Filer

Entity Small Business true

Entity Emerging Growth Company true

Entity Ex Transition Period true

Entity Shell Company false

Entity Common Stock, Shares Outstanding 54,247,501

Entity Central Index Key 0001634432

Current Fiscal Year End Date --12-31

Document Fiscal Year Focus 2020

Document Fiscal Period Focus Q1

Amendment Flag false

X

- Definition
Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
No definition available.
+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
End date of current fiscal year in the format --MM-DD.
+ References
No definition available.
+ Details

Name: dei_CurrentFiscalYearEndDate

Namespace Prefix: dei_

Data Type: xbrli:gMonthDayItemType

Balance Type: na

Period Type: duration

X

- Definition
Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalPeriodFocus

Namespace Prefix: dei_

Data Type: dei:fiscalPeriodItemType

Balance Type: na

Period Type: duration

X

- Definition
This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalYearFocus

Namespace Prefix: dei_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Definition
The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.
+ References
No definition available.
+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
No definition available.
+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.
+ References
No definition available.
+ Details

Name: dei_EntityCommonStockSharesOutstanding

Namespace Prefix: dei_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
No definition available.
+ Details

Name: dei_EntityCurrentReportingStatus

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate if registrant meets the emerging growth company criteria.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityEmergingGrowthCompany

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 7A
-Section B
-Subsection 2
+ Details

Name: dei_EntityExTransitionPeriod

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityFilerCategory

Namespace Prefix: dei_

Data Type: dei:filerCategoryItemType

Balance Type: na

Period Type: duration

X

- Definition
Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-T
-Number 232
-Section 405
+ Details

Name: dei_EntityInteractiveDataCurrent

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityShellCompany

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicates that the company is a Smaller Reporting Company (SRC).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntitySmallBusiness

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: sbbp_DocumentAndEntityInformationAbstract

Namespace Prefix: sbbp_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 59 R5.htm IDEA: XBRL DOCUMENT v3.20.1

Consolidated Statement of Stockholders’ Equity - USD ($)
$ in Thousands

Ordinary Shares

Maximum

Ordinary Shares

Deferred Shares

Additional Paid-In Capital

Accumulated Deficit

Accumulated Other Comprehensive Income

Total

Balance at beginning of period at Dec. 31, 2018 $ 541 $ 44 $ 323,402 $ (211,032) $ 112,955

Balance (in shares) at Dec. 31, 2018 54,122,074 40,000

Increase (Decrease) in Stockholders' Equity

Net loss (18,434) (18,434)

Stock-based compensation 2,323 2,323

Exercise of stock options $ 1 165 166

Exercise of stock options (in shares) 39,728

Ordinary shares issued, net of shares withheld for employee taxes $ 1 (27) (27)

Ordinary shares issued, net of shares withheld for employee taxes (in shares) 6,146

Balance at end of period at Mar. 31, 2019 $ 542 $ 44 325,863 (229,466) 96,983

Balance (in shares) at Mar. 31, 2019 54,167,948 40,000

Balance at beginning of period at Dec. 31, 2019 $ 542 $ 44 332,085 (260,483) $ 3 72,191

Balance (in shares) at Dec. 31, 2019 54,205,852

Increase (Decrease) in Stockholders' Equity

Net loss (12,698) (12,698)

Stock-based compensation 1,751 1,751

Ordinary shares issued, net of shares withheld for employee taxes $ 1 (68) (68)

Ordinary shares issued, net of shares withheld for employee taxes (in shares) 41,649

Unrealized gain on marketable securities 3 3

Balance at end of period at Mar. 31, 2020 $ 542 $ 44 $ 333,768 $ (273,181) $ 6 $ 61,179

Balance (in shares) at Mar. 31, 2020 54,247,501

X

- Definition
Number of stock issued as a result of the exercise of stock options, in net of tax settlement.
+ References
No definition available.
+ Details

Name: sbbp_StockIssuedSharesStockOptionsExercisedNetOfTax

Namespace Prefix: sbbp_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 20
-Section 55
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=118258462&loc=d3e11149-113907

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 20
-Section 55
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=118258462&loc=d3e11178-113907

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 35
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=116855982&loc=d3e4534-113899
+ Details

Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of unrealized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563
+ Details

Name: us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: us-gaap_IncreaseDecreaseInStockholdersEquityRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Number of shares issued which are neither cancelled nor held in the treasury.
+ References
No definition available.
+ Details

Name: us-gaap_SharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (d)(1)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Value of stock issued as a result of the exercise of stock options, after deduction of related income tax (expense) benefit.
+ References
No definition available.
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4I
-URI http://asc.fasb.org/extlink&oid=116874947&loc=SL4590271-111686

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683
+ Details

Name: us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 60 R25.htm IDEA: XBRL DOCUMENT v3.20.1

Stock-based compensation (Tables)
3 Months Ended

Mar. 31, 2020

Stock-based compensation

Schedule of summary of outstanding stock options activity

Options Outstanding







Weighted-



Average

Weighted-

Remaining

Average

Contractual

Number of

Exercise

Term

Aggregate

Shares

Price

(Years)

Intrinsic Value

(in thousands)

Outstanding—January 1, 2020

9,192,684

$

6.58

5.96

$

164

Granted

2,393,000

$

2.97

Forfeited and cancelled

(1,133,316)

$

10.66

Exercised

—

$

—

Outstanding—March 31, 2020

10,452,368

$

5.31

2.01

$

104

Vested and exercisable—March 31, 2020

5,100,335

$

6.86

5.39

$

6

Schedule of stock-based compensation

We recognized stock‑based compensation expense for employees and directors for stock options and RSUs as follows (in thousands):

Three Months Ended



March 31,

2020



2019

Selling, general and administrative

$

1,270

$

1,811

Research and development

481

512

Total stock-based compensation

$

1,751

$

2,323

Schedule of assumptions for estimating fair value of stock option awards

Three Months Ended

March 31,



2020



2019

Expected term (in years)

6.07

6.09

Risk-free interest rate

1.47%-1.48%

2.47%-2.61%

Expected volatility

78.15%-78.21%

80.00%-80.85%

Dividend rate

—%

—%

Schedule of summary of unvested RSUs

Number of

Shares

Outstanding—January 1, 2020

791,350

Granted

212,650

Forfeited

(17,200)

Vested

(61,000)

Unvested—March 31, 2020

925,800

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (h)(1)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14.F)
-URI http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901
+ Details

Name: us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 61 R21.htm IDEA: XBRL DOCUMENT v3.20.1

Marketable securities (Tables)
3 Months Ended

Mar. 31, 2020

Marketable securities

Schedule of amortized cost, gross unrealized holding gains, gross unrealized holding losses and fair value of available-for-sale debt securities by type of security

As of March 31, 2020

Amortized Cost

Net Unrealized Gain

Fair Value

Commercial paper

$

3,293

$

—

$

3,293

U.S. treasury securities

2,994

6

3,000

Total marketable securities

$

6,287

$

6

$

6,293

X

- Definition
Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-URI http://asc.fasb.org/topic&trid=2196928
+ Details

Name: us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 62 R9.htm IDEA: XBRL DOCUMENT v3.20.1

Revenue recognition
3 Months Ended

Mar. 31, 2020

Revenue recognition

Revenue recognition

3. Revenue recognition

Product sales, net

We sell Keveyis to one specialty pharmacy provider (the “Customer”), who is the exclusive distributor of Keveyis in the United States. The Customer subsequently resells Keveyis to patients, most of whom are covered by payors that may provide for government-mandated or privately negotiated rebates with respect to the purchase of Keveyis.

Revenues from sales of Keveyis are recognized when we satisfy a performance obligation by transferring control of the product to the Customer. Transfer of control occurs upon receipt of the product by the Customer. We expense incremental costs related to the set-up of contracts with the Customer when incurred, as these costs do not meet the criteria for capitalization.

Reserves for variable consideration

Revenues from sales of Keveyis are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established and that result from rebates, co-pay assistance and other allowances that are offered between us and the patients’ payors. There is no variable consideration reserve for returns as we do not accept returns of Keveyis. These reserves are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to the Customer) or a current liability (if the amount is payable to a party other than the Customer). Where appropriate, these estimates may take into consideration a range of possible outcomes that are probability-weighted for relevant factors such as our historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. Overall, these reserves reflect our best estimates of the amount of consideration to which we are entitled based on the terms of the contract. The amount of variable consideration that is included in the transaction price may be constrained, and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. Actual amounts of consideration ultimately received may differ from our estimates. We reassess our estimates on an ongoing basis. If actual results in the future vary from our estimates, we will adjust our estimates. Any such adjustments would affect net product revenue and earnings in the period such variances become known.

Trade Discount: We provide the Customer with a discount that is explicitly stated in our contract and is recorded as a reduction of revenue in the period the related product revenue is recognized. In addition, we receive sales order management, data and distribution services from the Customer. To the extent the services received are distinct from our sale of Keveyis to the Customer, these payments are classified in selling, general and administrative expenses in our consolidated statement of operations and comprehensive loss.

Funded Co-pay Assistance Program: We contract with a third-party to manage the co-pay assistance program intended to provide financial assistance to qualified insured patients. The calculation of the accrual for co-pay assistance is based on an estimate of claims and the cost per claim that we expect to receive associated with Keveyis that has been recognized as revenue, but remains in the distribution channel inventories at the end of each reporting period. These payments are consideration payable to the Customer and the related reserve is recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability which is included in accrued expenses on the consolidated balance sheet.

Government Rebates: We are subject to discount obligations under state Medicaid programs and Medicare. We estimate our Medicaid and Medicare rebates for the estimated patient mix. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability, which is included in accrued expenses on the consolidated balance sheet. For Medicaid, accruals are based on estimates of future Medicaid beneficiary utilization applied to the Medicaid unit rebate formula established by the Center for Medicaid and Medicare Services. Effective January 1, 2019, manufacturers of pharmaceutical products are responsible for 70% of the patient’s cost of branded prescription drugs related to the Medicare Part D Coverage Gap. In order to estimate the cost to us of this Medicare coverage gap responsibility, we estimate the number of patients in the prescription drug coverage gap for whom we will owe an additional liability under the Medicare Part D program. Our liability for these rebates consists of estimates of claims for the current quarter and estimated future claims that will be made for Keveyis that have been recognized as revenue, but remains in the distribution channel inventories at the end of each reporting period.

Temporary Supply and Patient Assistance Programs: We provide free Keveyis to uninsured patients who satisfy pre-established criteria for either the Temporary Supply Program or the Patient Assistance Program. Patients who meet the Temporary Supply Program eligibility criteria may receive a temporary supply of free Keveyis for no more than sixty days while there is a determination of the patient’s third-party insurance, prescription drug benefit or other third-party coverage for Keveyis. The Patient Assistance Program provides free Keveyis for up to twelve months to uninsured patients who satisfy pre-established criteria for financial need. We do not recognize any revenue related to these free products and the associated costs are classified in selling, general and administrative expenses in our consolidated statements of operations and comprehensive loss.

X

- Definition
Disclosure pertaining to revenue.
+ References
No definition available.
+ Details

Name: sbbp_RevenuesDisclosureTextBlock

Namespace Prefix: sbbp_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_RevenueFromContractWithCustomerAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 63 R40.htm IDEA: XBRL DOCUMENT v3.20.1

Commitments and contingencies - Commitments to Taro (Details) - Acquired product rights - Keveyis
$ in Millions
1 Months Ended

Mar. 31, 2017

USD ($)

Dec. 31, 2016

USD ($)

installment

Mar. 31, 2020

USD ($)

Other Commitments

Number of installment payments | installment 2

Installment payment $ 7.5 $ 1.0

Potential milestone payments 7.5

Minimum amount of purchases obligated $ 29.0

Purchase obligation period 6 years

Remaining obligation $ 19.0

X

- Definition
Represents the amount of potential payments that could be paid under the collaborative agreement.
+ References
No definition available.
+ Details

Name: sbbp_CollaborativeArrangementMilestonePaymentsPotential

Namespace Prefix: sbbp_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Represents the period of time the company is obligated to purchase product under the arrangement.
+ References
No definition available.
+ Details

Name: sbbp_CollaborativeArrangementPeriodOfPurchaseObligation

Namespace Prefix: sbbp_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents the number of installment payments.
+ References
No definition available.
+ Details

Name: sbbp_NumberOfInstallmentPayments

Namespace Prefix: sbbp_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: instant

X

- Definition
Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.
+ References
No definition available.
+ Details

Name: us-gaap_ContractualObligation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_OtherCommitmentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585
+ Details

Name: us-gaap_PaymentsToAcquireIntangibleAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.
+ References
No definition available.
+ Details

Name: us-gaap_PurchaseObligation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=sbbp_AcquiredDevelopedProductRightsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_ProductOrServiceAxis=sbbp_KeveyisMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 64 R44.htm IDEA: XBRL DOCUMENT v3.20.1

Stock-based compensation - Stock options activity (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 12 Months Ended

Mar. 31, 2020

Dec. 31, 2019

Summary of outstanding stock options

Outstanding at beginning of period (in shares) 9,192,684

Granted (in shares) 2,393,000

Forfeited and cancelled (in shares) (1,133,316)

Outstanding at end of period (in shares) 10,452,368 9,192,684

Vested and exercisable at end of period (in shares) 5,100,335

Weighted-Average Exercise Price

Granted (in dollars per share) $ 2.97

Forfeited and cancelled (in dollars per share) 10.66

Outstanding (in dollars per share) 5.31 $ 6.58

Vested and exercisable at end of period (in dollars per share) $ 6.86

Additional Disclosures - Options

Weighted Average Remaining Contractual Term, Outstanding 2 years 4 days 5 years 11 months 16 days

Weighted Average Remaining Contractual Term, Vested and exercisable 5 years 4 months 21 days

Aggregate Intrinsic Value, Outstanding (in dollars) $ 104 $ 164

Aggregate Intrinsic Value, Vested and exercisable at end of the period (in dollars) $ 6

X

- References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(3)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Gross number of share options (or share units) granted during the period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Number of options outstanding, including both vested and non-vested options.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)-(ii)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration